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Abstract 
Background: Downhill running involves eccentric contractions of the gluteal, quadriceps, hamstring and 
calf muscles and the lengthening of muscle fibres as they contract. Several studies have demonstrated that 
this type of prolonged eccentrically biased exercise induces tissue damage and subsequent enhancement of 
an inflammatory response. 
Traumeel® S (Heel GmbH, Baden-Baden, Germany) is a homeopathic-complex used to treat trauma and 
inflammatory processes that is sold as an over the counter remedy in pharmacies. Although the anti-
inflammatory and analgesic effects of Traumeel® S have been demonstrated in selected clinical trials as 
well as in in vitro experimental models, little is known of its scientific mechanisms of action. 
Aim: The aim of this study was to establish whether administration of Traumeel® S five days before and 
three days after a 90-minute downhill treadmill run at 75% V02 peak significantly changes systemic 
markers of the inflammatory response. These are to include blood-borne concentrations of Cortisol and 
examples of selected T-helperrcell cytokines, T-helper2-cell cytokines, chemokines and pro-inflammatory 
cytokines during the three days following the 90-minute downhill run. 
Method: This study was designed as a double-blinded, placebo-controlled clinical trial in which matched 
subjects were randomised to Traumeel (TRAU) and Placebo (PLAC) pairs and exposed to two 90-minute 
downhill running trials. 
Twenty subjects (12 men, 8 women) aged between 20 and 50 years, fully complied with all inclusion 
criteria set for the study. Following baseline laboratory and field testing, they were matched according to 
gender, body mass index (BMI), training age, training status, peak running performance and foot-strike 
patterns and randomized into TRAU and PLAC groups. One Traumeel® S tablet was ingested three times 
per day for five days prior to and three days following a 90-minute downhill run on a treadmill at a -6% 
gradient and at a speed eliciting 75% V02 peak on a level gradient. Blood samples were obtained 
immediately before the 90-minute trial (PRE), immediately after the trial (IPE) and 24 hours (24 PE), 48 
hours (48 PE) and 72 hours (72 PE) following the trial. Each subject was also requested to complete a 
training record prior to the trial and keep a record of the daily symptoms of delayed onset muscle soreness 
(DOMS) both at rest (general pain) and while walking (daily living). 
Full blood counts, serum creatine kinase (CK) and Cortisol concentrations were determined using standard 
haematological laboratory procedures. A sandwich ELISA was used to determine plasma interleukin-6 
(IL-6) concentrations. A commercial bead-array kit was used to conduct flow cytometric analysis of 
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Interleukin-8 (IL-8), Interleukin-10 (IL-10), Tumour Necrosis Factor alpha (TNFa), and Interleukin-12p70 
(IL-12p70) concentrations. 
Results: Paired student Mests indicate that the mean ± SEM of the two groups was not significantly 
different (p < 0.05) in terms of age, BMI, percentage body fat, training age, foot strike patterns, running 
performance, FVC, FEV1; baseline heart rate and blood pressure, RERmax, V02 peak, VEmax, or training 
status. Although the TRAU group completed the 90-minute downhill running trial at a significantly faster 
speed (13.3 ± 2.1 vs. 12.8 ±0.3 km.hr; p = 0.02) and covered a greater distance (20.1 ± 0.3 vs. 19.34 ± 
0.4; p = 0.03), mean and maximum heart rate and RPE did not differ between trials in the TRAU and 
PLAC groups. The downhill running protocol resulted in significant increases in neutrophil counts and 
creatine kinase, Cortisol, IL-6, IL-8 and IL-10 concentrations in the circulation (n = 20; p < 0.001). When 
comparing the TRAU (n = 10) and PLAC (n = 10) groups, blood neutrophil counts, creatine kinase, 
Cortisol, and IL-6 concentrations over the 5 time points and PRE, IPE and 24 PE plasma TNF, IL-8, EL-10 
and EL-12p70 concentrations did not differ significantly (p > 0.05). Blood creatine kinase was, however, 
significantly higher in the TRAU group at 24PE (p < 0.05). The post-trial DOMS scores reported by the 
TRAU group over the 3-day post-exercise recovery period were also significantly lower in the TRAU 
group at 24PE (p = 0.03). 
Conclusion: Despite a faster running speed and higher post trial CK concentration in the TRAU group 
following the 90-minute downhill run, statistically significant differences in circulating stress hormone, 
and cytokine concentrations (IL-6, IL-8, IL-10, TNFa and IL-12p70) between the TRAU and PLAC 
groups, were not identified. Delayed onset muscle soreness was also significantly lower in the TRAU 
group at 24 hours post trial (p = 0.03). While these findings would support attenuation of the post-exercise 
inflammatory response by Traumeel® S, further work is required to verify this possibility. 
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1.1. Introduction to the Problem 
Exercise of an intense and prolonged nature has been known to cause microscopic muscle damage, 
generating an inflammatory response and causing numerous immune perturbations (Peters, 1997; Nieman, 
2000; Pedersen, 2001). This is particularly evident after downhill running, during which the eccentric work 
of the 'anti-gravity' knee extensor muscles and the anterior and posterior tibial muscles as well as the hip 
extensors is accentuated and the muscles are forcibly lengthened while contracting (Eston et al., 1995). 
Post-exercise leukocytosis has been reported to occur within a few hours after the cessation of intense 
prolonged exercise (McKinnon, 1999, Nieman, 2000). This is attributed to immediate post-exercise 
neutrophilia and subsequent monocyte migration to the site of tissue disruption which begins several hours 
after neutrophil migration (Moshage, 1997). Following eccentric exercise, the debris produced by the 
muscle damage activates macrophages resident in the muscle tissue, which produce polypeptide messenger 
molecules known as cytokines. These play an important role in the inflammatory response and the 
subsequent clearance of the cell debris from the site of exercise induced muscle damage (Suzuki, 2002). 
1.2. The Effect of Traumeel On Inflammatory Markers in the Blood 
Traumeel® S (Heel GmbH, Baden-Baden, Germany) is a homeopathic-complex remedy used to treat 
trauma and inflammatory processes. It is a mixture of highly diluted (lO'-lO9) extracts from medicinal 
plants and minerals that is sold as an over the counter remedy in pharmacies in many countries. Its anti-
inflammatory and analgesic effects have been demonstrated in clinical trials as well as in in vivo 
experimental models, including the carrageenin-induced oedema test and the adjuvant arthritis test 
(Conforti etai, 1997; Schmotz, 1998). 
Traumeel® S has been reported to be non-cytotoxic to granulocytes, lymphocytes, platelets and 
endothelial cells and the intracellular processes of these cells are not impaired by Traumeel® S (Conforti 
et al., 1997; Porozov et al., 2004). The anti-inflammatory effect has been proposed to be the result of the 
activity of single components on the different phases of inflammation (Conforti et al., 1997, Porozov et al., 
2004). Its efficacy in attenuating inflammatory processes involving muscles and joints, sprains and bruises 
has been demonstrated in placebo-controlled experimental and clinical studies (Conforti et al., 1997; Heine 
and Schmotz, 1998; Porozov et al., 2004). The mechanism by which Traumeel® S exerts its therapeutic 
effects however, remains to be clarified and its possible effects on the behaviour of immune cells, requires 
detailed investigation. 
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In vitro experiments revealed that interleukin-ip (IL-ip) activation was reduced by up to 70%, tumor 
necrosis factor-a (TNF-a) activation was reduced by up to 65% and interleukin-8 (IL-8) activation was 
reduced by 50% following the administration of Traumeel® S to in vitro immune cells (Human T cells, 
monocytes, and gut epithelial cells). Traumeel® S did not appear to affect T-cell and monocyte 
proliferation and maximal inhibition was maintained with dilution of the Traumeel® S stock material 
(Conforti et ai, 1997; Porozov et ai, 2004). In studies conducted on whole blood cultures, elevations in 
the concentration of Transforming Growth Factor Beta (TGF-6), which is a cytokine synthesized by Type 
3 T-Helper (Th3) lymphocytes, were reported after administration of Traumeel® S (Heine & Schmotz, 
1998). 
In an in vivo study conducted by Jordaan (2006), 50 actively participating marathon runners were divided 
into a control (n - 24) and an experimental group (n = 26). The subjects used the Traumeel® S or placebo 
administration for seven days and followed their normal training programme. On the eighth day subjects 
underwent a downhill run on a treadmill at 75% of peak treadmill speed for 45 minutes at a gradient of -
10%. Post exercise blood samples were drawn at the same time of day for four days (24hr, 48hr, 72hr, and 
96hr post-exercise). The results of this study did not reveal significant changes in serum creatine kinase 
concentrations, or neutrophil, monocyte, basophil, eosinophil and lymphocyte counts. It was, however, 
reported that circulating Cortisol concentrations in the Traumeel® S group were higher than in the placebo 
group at 48hr, 72hr and 96hr post-exercise, although immediate post-exercise concentrations were not 
reported (Jordaan, 2006). 
The aim of the study is therefore to extend upon the work conducted by Jordaan (2006), focusing more 
deeply on systemic markers of inflammation with specific reference to cytokines. 
1.3. Aims and Objectives of the study 
1. To determine whether 90-minutes of downhill treadmill running at 75 % V02 peak results in an 
elevation of neutrophils, muscle enzyme (creatine kinase; CK), stress hormone (Cortisol), type 1 
T-helper (Thl) cytokine (IL-12p70), type 2 T-helper (Th2) cytokine (IL-6, IL-10), chemokine (IL-
8) and pro-inflammatory cytokine (TNF-a) concentrations in the circulation. 
2. To establish whether administration of Traumeel® S five days before and for three days after 90-
minute downhill run significantly attenuates the above-mentioned systemic markers of muscle 
damage and/or an inflammatory response during the 72 hours following the trial. 
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1.4. Hypotheses 
In keeping with the consistent findings in the literature regarding inflammatory response to downhill 
running and eccentric exercise (Pedersen et al., 1999; Malm et al., 2004 Peake et al., 2005a; McKune et 
al, 2006), the following one directional alternate hypothesis was set: 
Downhill running will result in an elevation of neutrophil count, creatine kinase, Cortisol and 
pro/anti- inflammatory cytokine concentrations in the circulation. 
In the absence of consistent findings in in vivo exercise intervention studies following administration of 
Traumeel® S, the following null hypothesis was set prior to the onset of the work: 
Administration of Traumeel® S will not induce changes in post-exercise circulating stress 
hormone, IL-12p70, IL-6, IL-10, IL-8 and TNF-aconcentrations following a 90-minute downhill 
run at 75% V02max. 
1.5. Limitations and Scope of the study 
Due to the undisputed evidence which is now available regarding the repeated bout effect viz. the adaptive 
response to acute repeated exposure to similar bouts of eccentric exercise (Nosaka et al., 2005; McHugh, 
2003; Nosaka and Newton, 2002; Stupka et al., 2001), it was not possible to conduct a crossover study. In 
order to eliminate a training effect as a potential confounder in the study, this double-blind, placebo-
controlled study was therefore designed using pairs of runners who were as closely matched as possible to 
ensure sufficient external validity. As it was also necessary to design this study within the framework of 
financial constraints as well as difficulty in obtaining full compliance from the subjects, the sample size 
was restricted to 10 gender-matched couples (n = 20). 
Two groups of ten (n = 20) ultradistance runners, who were matched for gender, Body Mass Index (BMI), 
training age, training status as well as at least two of the following: running biomechanics (foot-strike 
pattern), peak oxygen consumption (V02peak), 1609m running time and/or best performance in endurance 
running events within six months prior to commencement of the study, were randomised to Traumeel 
(TRAU) and Placebo (PLAC) trials in a strictly double-blinded protocol. 
After field testing on an athletics track and maximal exercise test in a Human Performance Laboratory, 
each subject completed a -6 % downhill 90-min treadmill run at 75% V02 peak. 
Each subject ingested either a Traumeel preparation or a placebo (in tablet form) provided by Heel Pty 
Ltd., three times a day for five days prior to the 90-minute downhill trial. Circulating concentrations of 
neutrophils, CK, Cortisol, and cytokine concentrations (TNFa, IL-6, IL-8, IL-10, IL-12p70), were 
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measured from venous blood samples taken pre-, immediately post (IPE), 24 hours post (24PE), 48 hours 
post (48PE) and 72 hours post (72PE) each exercise-trial, to establish whether a significant difference 
existed between each of the trials over the 4-day post-exercise recovery time-period. Subjective 
perceptions of post-exercise delayed onset muscle soreness (DOMS) were also monitored during the 72 
hours following each exercise trial. 
Chapter 2 
Review of the Related Literature 
2.1. Eccentric Exercise and Muscle Damage 
Prolonged strenuous exercise has been shown to cause perturbations in immune function (Pedersen and 
Hoffman-Goetz, 2000). For a few hours following heavy exertion, several components of the innate and 
adaptive immune system are changed; white cell and neutrophil counts are raised, while lymphocyte 
numbers are reduced (Nieman, 2000). Many theories have been proposed as to the mechanisms behind this 
temporary alteration in immune function, including hormone-induced trafficking of immune cells and the 
direct influence of increased concentrations of stress hormones, prostaglandins, cytokines, leukocytes and 
expression of adhesion molecules (Suzuki et ai, 1999, 2000; Smith et ai, 2000). 
Several studies have demonstrated that unaccustomed eccentrically biased exercise which involves 
lengthening of muscle while it is contracting, induces tissue damage. Although downhill running is a 
functional activity involving both concentric and eccentric contraction, there is a longer period during 
which the knee extensors and ankle flexors are being actively strained and the anterior-posterior braking 
impulse is almost double that of the propulsive impulse than during level running (Eston et ai, 1995). 
Towards the end of the recovery phase of the downhill running gait, the hamstring muscles contract 
eccentrically to decelerate the forward swing of the lower limb that was initiated by the quadriceps 
(Petersen and Holmich, 2005). The knee extensor muscles then contract as they are lengthened after the 
foot touches the ground and the centre of mass is decelerating. In the lower leg, the ankle plantar flexors 
also work eccentrically to control the forward movement of the leg over the foot in early stance phase and 
facilitate heel lift, while ankle dorsiflexors have an eccentric work component as they control the descent 
of the forefoot. Following downhill running, eccentric muscle contraction therefore occurs in the gluteal, 
quadriceps, hamstring, and both anterior and posterior tibial muscles (Paul et ai, 1978; Eston et ai, 1995). 
Maclntyre et al. (1995) suggest that eccentric exercise results in a greater amount of tension per active 
motor unit than concentric contraction during which the muscles shorten while contracting. Peake (2005a) 
further describes how during repeated eccentric contractions, first the weak and then the stronger 
sarcomeres, are progressively overstretched and the failure of the sarcomeres to reconnect, results in their 
disruption. When the muscle lengthens in an eccentric contraction, there may also be shearing of the 
myofibrils, specifically at the obliquely arranged fibres which occur at the musculotendinous junction 
(Noonan and Garrett, 1992). Ultrastructural damage occurs to the Z disks that anchor the myofilaments 
and several intermediate filaments within the sarcomere. Z disks appear to widen or disintegrate. While 
regional disorganisation and transverse tubule damage have been identified in electron microscopic studies 
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(Proske and Morgan, 2001; Grobler et al, 2004), this structural disruption has also been reported to spread 
to adjacent areas of the muscles and can ultimately lead to damage to the membranes of the sarcoplasmic 
reticulum or the sarcolemma (Friden and Lieber, 2001). Disturbances of mitochondria, A-band and 
separation of the myofibrils have been reported (Peake, 2005a). In addition to the loss of cellular integrity 
which occurs early during heavy eccentric exercise, exercise-induced tissue damage has also been shown 
to include loss of the non-contractile cytoskeletal proteins, desmin, titin, nebulin and alpha-actin (Stupka et 
al, 2000; Friden and Lieber, 2001; Amat et al, 2007). 
Several theories have been postulated in order to explain the increased muscle stiffness observed following 
eccentric exercise. It is proposed that the acute decrease in muscle compliance could be due to an increase 
in the Ca2+ ions released following myofilament and sarcolemmal disruptions (Friden and Lieber, 1992; 
Jones et al, 1997; Whitehead et al, 2001). Swelling which may occur in and around the muscle and 
increase the pressure on adjacent structures, may also result in greater stiffness (Ross, 1999). 
Damage to the muscle membrane also causes the leakage of muscle proteins including CK, lactate 
dehydrogenase, troponin-I, alpha-actin and myoglobin into the blood steam (Malm, 1999, Peters et al, 
2005, Amat et al, 2007). Abnormally high circulating levels of enzymes such as CK are therefore taken to 
reflect changes in the integrity of muscle fibre membranes, either as a result of damage to, or increased 
permeability of the membrane to the enzyme (Eston et al, 1995). Elevated serum concentrations of CK 
have consistently been measured following eccentric activation of muscle as occurs during downhill 
running. When compared to the normal reference range for CK of 45-135 u/L (Hirose et al., 2004), 
Mckune et al (2006) found that a 60-minute bout of downhill running at a -13.5% gradient resulted in 
mean CK concentrations of 1241 (± 134.6) u/L six hours post-exercise, 1133.7 (± 118.1) u/L 12hr post-
exercise and 826.8 (± 105.3) u/L 24hr post-exercise. Jordaan (2006) reported pre-exercise CK 
concentrations in the blood of 251 (± 171) u/L in the Traumeel® S group and 324 (± 439) u/L in the 
placebo group, while 24h post exercise CK concentrations reached 422 (± 424) u/L in the Traumeel® S 
group and 599 (± 448) u/L in the placebo group, returning to pre-exercise levels by 48hrs post-exercise. 
The clearance of muscle cell debris from the site of exercise-induced muscle damage is initiated by 
macrophages that are resident in muscle tissue. They produce cytokines which increase cell membrane 
permeability and the influx of lymphocytes, neutrophils, monocytes to the damaged tissue, and activate the 
release of Cortisol from the adrenal cortex and acute phase proteins from the liver. This facilitates an 
inflammatory reaction and results in the clearance of the cell debris and subsequent healing of the tissue 
(Pedersen, 2000; Pedersen and Hoffman-Goetz, 2000; Pedersen et al, 2001). 
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2.2. Cytokines and Exercise 
2.2.1. Introduction 
Cytokines are a diverse family of intracellular polypeptides that have a signaling function and exert 
important influences on inflammatory and immune processes as well as hematopoesis (Suzuki et ai, 
1999). They are divided into several different families including the interleukins, tumor necrosis factors, 
growth factors and colony stimulating factors (Smith, 2000). These have also been classified according 
their functions into those that mediate natural immunity, regulate lymphocyte activation, growth and 
differentiation, activate inflammatory cells, and stimulate hematopoesis (Suzuki et ai, 1999,2000; 
Pedersen et ai, 2001; Suzuki et ai, 2002). Table 2.1.outlines some of the most commonly measured 
cytokines which fall into these categories, the cells which secrete them, their target cells and their 
general functions in the immune system. 
Table 2.1: Five categories of cytokines commonly measured in exercise studies* 
Cytokine 
Classification 















































Activated T and 









cells, Th2 cells 
Induction and expression of adhesion molecules on 
leucocytes and induction of inflammatory response 
which activates vascular endothelium increasing its 
permeability and expression of IL-(3; IL-6; IL-8 
Co-stimulation of Thl cells, maturation and 
proliferation of B cells, activation of NK cells, 
inflammation, acute phase response, fever 
Co-stimulation of Th2 helper cells, maturation and 
proliferation of B cells, activation of NK cells, 
inflammation, acute phase response, fever 
Proliferation and differentiation of Th-cells, 
IgGi and IgE synthesis, mediates recruitment and 
activation of mast cells 
Inhibition of macrophage derived release of TNF-cc; 
IL-2, IL-3, IFN-y, suppress antigen presentation by 
macrophages 
Stimulation of the growth and proliferation of Th 1 -
cell lymphocytes, facilitate production of 
immunoglobulins made by B cells and induces the 
differentiation and proliferation of NK cells 
Proliferation and differentiation 
IgA synthesis 
Differentiation into CTL 
(with IL-2), activation of NK cells 
Viral replication 







































Differentiation into plasma cells, antibody secretion, 
activates the acute phase response, stimulates 
immune response to tissue damage following 
trauma, involved in regulation of hematopoesis, 
stimulation of Cortisol release from adrenal medulla, 
signal in the synthesis of plasma proteins 
Phagocytosis, cell death 
Increasing IL-1 production by activated 
macrophages, inducing a class switch to IgA 
proliferating B cells 
Acting as chemoattractant for monocytes and 
macrophages 
Inhibiting the proliferation of cells required for the 
inflammatory process 
Chemotaxis of neutrophils, basophils, eosinophils, 
T-lymphocytes 
Progenitor cells Growth and differentiation of monocytes and DC 
MHC: Major histocompatibility complex; NK cells: Natural killer cells, CAM: Cell adhesion molecules, IgA: Immunoglobulin A, 
CTL: Cytotoxic T Lymphocytes, Tc-cells: Effector cytolytic T lymphocytes. *Suzuki et ai, 1999; Pedersen et ai, 2001; Suzuki et 
ai, 2000, 2002; Smith, 2000; Bagby etal, 1996; Peters, 2004; Pedersen and Hoffman-Goetz, 2000. 
2.2.2.2. Pro-Inflammatory cytokines 
2.2.1. Tumor Necrosis Factor Alpha (TNF-a) 
Tumor Necrosis Factor Alpha (TNF-a), also sometimes referred to as cachexin and cachectin, initiates the 
systemic inflammatory response and is an important component of the acute phase reaction mediating 
hepatic release of several acute phase proteins. It is secreted mainly, but not exclusively, by macrophages 
and NK cells (Smirnova et ai, 2003). It is also produced by other cells including lymphoid cells, mast 
cells, endothelial cells, cardiac myocytes, adipose tissue, fibroblasts and some neuronal tissue. It primarily 
targets macrophages and tumor cells. 
The synthesis and release of TNF-a by tissue macrophages that are activated after engulfing and degrading 
foreign or microbial organisms, has important local and systemic effects. The major local effect of TNF-a 
is to initiate an inflammatory response. The vascular endothelium is activated resulting in an increase in 
vascular diameter and leading to increased local blood flow and redness. Vascular permeability is also 
increased resulting in the accumulation of fluid (swelling), immunoglobulins, complement and other blood 
proteins (Tracey and Cerami, 1993; Bagby et ai, 1996; Ganong, 2005). 
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TNF-a is also instrumental in inducing the expression of adhesion molecules on the endothelium. These 
bind to the surface of leukocytes and increase the rate at which these cells (particularly neutrophils), 
diapedese through small blood vessel walls into the tissues. In this manner large numbers of monocytes 
and polymorphonuclear leukocytes migrate to the site of infection or inflammation (Nieman, 1997; Malm 
et al, 1999; Pederson and Toft, 2000). 
A further important molecular change induced by TNF-a at the endothelial cell surface is induction of the 
expression of molecules that trigger blood clotting in small blood vessels. This assists in containing the 
inflammatory response and preventing its spread into the blood stream which can be deleterious (Ganong, 
2005; Stenvinkel et al, 2005; Juge-Aubry et al, 2005). 
TNF-a has various functions including pro-inflammatory cytokine expression, apoptosis (cell death), 
cellular proliferation and differentiation, tumorigenesis, and viral replication. Its primary function is, 
however, the regulation and mediation of an inflammatory response. When this function is altered, and 
over or underproduction of TNF-a occurs, a variety of human diseases and syndromes, ranging from the 
overtraining syndrome (OTS) experienced by some athletes to malignancy, have been reported to occur 
(Tracey and Cerami, 1993; Taylor, 2002; Smirnova et al., 2003; Smith, 2004; Stenvinkel et al., 2005; 
Juge-Aubry et al, 2005). 
In conjunction with the IL-1 family and IL-6, TNF-a also has many effects on end organs such as the liver 
and hypothalamus as a result of their secretion into the circulation. These are summarized in Table 2.2. 
Table 2.2: The effects of TNF-a on end organs 
Organ/Tissue Effect 
Liver Stimulates and mediates the acute phase response and consequently increases 
circulating concentrations of C-reactive protein (CRP) and other mediators. It causes 
insulin resistance by promoting serine-phosphorylation of insulin receptor substrate-1, 
which inhibits insulin signaling. 
Macrophages Activates phagocytosis, production of IL-1 and the inflammatory lipid prostaglandin 
E2 (PGE2). 
Hypothalamus Activates the hypothalamic-pituitary-adrenal axis causing the release of corticotropin 
releasing hormone (CRH), appetite suppression and pyrexia. 
Other tissue: Attracts neutrophils very strongly and aids in their adhesion to endothelial cells. 
Increasing concentration of TNF will cause the cardinal signs of inflammation to 
occur: heat, swelling, redness, clotting and pain. 
High systemic concentrations of TNF may precipitate shock-like symptoms. 
Tracey and Cerami 1994; Taylor, 2002; Smirnova et al, 2003; Juge-Aubry et al, 2005; Smith, 2003; 2004) 
Release of TNF-a into the bloodstream can, however, also have damaging effects. These include systemic 
oedema, hypoproteinemia and neutropenia associated with disseminated intravascular coagulation, 
depletion of clotting factors, multiple organ failure and death (Stenvinkel et al., 2005; Juge-Aubry et al., 
2005). 
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Several exercise studies have examined concentrations of TNF-a post exercise. These are summarised in 
Table 2.3. Although some studies revealed a slight mean increase, ranging from 0.1 to 4.3 fold, 
immediately post exercise (Ostrowski et al., 1998a, 1999; Nieman et al. 2000; Toft et al., 2000; Starkie et 
al., 2001; Smith et al., 2007), the reported values all remain within physiologically normal ranges (Suzuki 
et al, 2002). 
Numerous reports (Croisier et al, 1999; Toft et al, 2002; Hirose et al., 2004) in particular those following 
eccentric exercise (Hirose et al, 2004), however, indicate that there is not a significant exercise-induced 
increase in this pro-inflammatory cytokine concentration in the circulation during exercise. Several 
factors may account for this. On the one hand, the half-life of circulating TNF-a is short (14 - 18 
minutes) and the kidney is a major organ for TNF clearance. A rapid renal clearance from the circulation 
into the urine has therefore been suggested as one of the reasons for the failure of TNF-a concentrations 
in venous blood to be elevated post exercise (Suzuki et al., 2002). Exercise has also been shown to 
stimulate the release of soluble TNF-a receptors which inactivate systemic TNF-a release (Ostrowski et 
al, 1999b). 
2.2.2.2. Interleukin lp (IL-lp) 
Interleukin-ip is a pro-inflammatory cytokine which is involved in the defence against foreign pathogens. 
It is produced by activated macrophages, dendritic cells and B-cells (Ganong, 2005). It targets T-helper 
(Th) cells, B-lymphocytes, NK cells and is responsible for the co-stimulation of Th2-cells, the maturation 
and proliferation of B cells, and the activation of NK cells. (Bagby et al, 1996; Pedersen and Hoffman-
Goetz, 2000; Smith, 2000; Suzuki et al, 2002; Peters, 2004). 
As does TNF-a it has been shown to increase the expression of adhesion factors on endothelial cells to 
enable the movement of leukocytes to the infection site in the tissue (Ganong, 2005, Stenvinkel et al, 
2005). It also helps to activate thermoregulatory center in the hypothalamus, leading to an elevation of 
body temperature (pyrexia) and is therefore referred to as an endogenous pyrogen (Bagby et al, 1996; 
Huising et al., 2004; Juge-Aubry et al., 2005). Its production in peripheral tissue has also been associated 
with hyperalgesia (increased sensitivity to pain) associated with pyrexic states (Dinarello, 1994; Dunn et 
al, 2001; Juge-Aubry et al, 2005). In keeping with these systemic effects, Smith (2003; 2004) reported 
that increased levels of interleukin 1P may be responsible for the effects of over training syndrome (OTS) 
in endurance athletes. 
Pro-inflammatory cytokines act in concert with specific cytokine inhibitors and soluble anti-
inflammatory cytokine receptors (the IL-1 receptor antagonist (IL-lra), TNF-a receptors, IL-4, and IL-
10) to regulate the inflammatory response to exercise induced microtrauma (Richards and Gauldie, 
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1995), thus their physiologic role in inflammation and pathologic role in systemic inflammatory states 
are increasingly recognized (Dinarello, 1994; Richards and Gauldie, 1995). 
The reported changes in IL-ip concentration in venous blood following exercise longer than 2hrs 
duration is summarized in Table 2.3. Although a few studies have reported increases in concentration of 
up to 200% (Nieman et al., 2000; Ostrowski et al., 1999), Ostrowski et al. (1998b) only report increases 
of 50% and other studies have reported no change (Suzuki et al., 2000). 
The inconsistencies in the literature with regard to IL-1(3 levels following exercise are attributed to 
different measurement intervals, differing measurement techniques and differences in exercise protocols 
between studies (Ostrowski et al., 1998b; 1999; Suzuki et al, 2002; Smith et al., 2007). A further factor 
to which inconsistencies could be attributed, is failure to adjust for the haemoconcentration which so 
frequently occurs following prolonged intense exercise (Mucci et al., 2000). 
It has been reported that the relatively lesser increment in TNF-a and IL-ip concentrations may be due to 
the release of the above-mentioned cytokine inhibitors in the blood (including IL-lra, TNF-a antagonists 
and the anti-inflammatory cytokine IL-10). These may restrict the magnitude and duration of the pro-
inflammatory response to exercise (Ostrowski et al., 1998b; 1999; Suzuki et al., 2002; Smith et al., 2007). 
Table 2.3 Pro-Inflammatory response to endurance exercise longer than 2hr in duration with 
specific emphasis on TNF-a and IL-ip concentrations in venous blood 
Author/s 
Ostrowski et al, 
1998b 
Ostrowski et al, 
1999 
Nieman et al., 2000 
Petersen/, 2001a 
Peters etal, 2001b 
Starkie et al, 2001 
Suzuki et al, 2003 
Methodology 
16 male marathon runners, marathon race, 
mean: 3h, 17min 
10 male marathon runners, marathon race, 
mean: 3h, 27min 
98 marathon runners, marathon race, mean: 
3.8h 
16 runners, 90km ultramarathon, 9-10h 
29 runners, 90km downhill ultramarathon, 
9-1 Oh 
5 male runners, marathon race, 2h-31min -
3h 25min 
10 male endurance athletes, 42 km marathon 
Results/Changes 
TNF-~: 2.5 \ (Post), 1.9 ] (Post2h), 
IL - 1(3: 50% t (Post), NC (Post l-4h 
TNF-<K 2 times | (Post-Post 1.5h)), 
Gradually^ to NC (Post 3.5h), IL -
IP: 1.5 -2 times | (Post-Post 0.5h), 
NC (Post l-4h, 
TNF-<x 10% t (Post), NC (Days 1 
and 2), IL - 1(5: 2 times | (Post), NC 
(Days 1 and 2 
TNF-os NC (Pre, Post, 24h and 48h 
post) 
TNF-o< NC Pre, Post, 24h and 48h 
post) IL.-1 p: NC Pre, Post, 24h and 
48h post) 
TNF-«. 4.3 times t (Post), 4 times | 
(Post 2h), NC (Days 1 and 2 










NC: No change; ND: non detectable; P: Plasma 
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2.2.3. Multifunctional Cytokines 
2.2.3.1. Interleukin-6 (IL-6) 
IL-6 is one of the most frequently measured cytokines in exercise immunology. Secreted by T-cells, 
fibroblasts, vascular endothelial cells and macrophages to stimulate the immune response to tissue damage 
following trauma (Bagby et al, 1996), it is produced in larger amounts than any other cytokine following 
exercise. It has also been found to be produced by muscle during exercise and has hence been referred to 
as a myokine (Pedersen et al, 2001). Its level is markedly increased in plasma following activity involving 
severe eccentric exercise and has been reported to increase by more than 100 fold following marathon and 
ultra-marathon races. (Ostrowski et al., 1999; Starkie et al, 2001; Table .2.4). 
Increased plasma concentrations of IL-6 have been shown to act on the hypothalamic pituitary axis (HPA) 
at three levels: 
1. the hypothalamus by stimulating secretion of corticotropin releasing hormone (CRH) 
2. anterior pituitary corticotropes by eliciting adrenocorticotropic hormone (ACTH) release 
3. the adrenal gland by enhancing steroid hormone secretion by adrenocortical cells 
Sstimulation of the adrenal cortex to increase its release of Cortisol into the blood stream has in turn been 
shown to stimulate the release of a number of compensatory anti-inflammatory cytokines, such as IL-10 
and IL-1 receptor antagonists (Bagby et al, 1996; Suzuki et al, 1999; Pedersen and Hoffman-Goetz, 
2000; Suzuki et ai, 2000; Smith, 2000; Pedersen et al, 2001; Peters, 2004). 
IL-6 also causes hepatocytes to synthesize plasma proteins such as fibrinogen which contribute 
significantly to the acute phase response (Tilg et al., 1994; Suzuki et ai, 1999). The activation pathway of 
IL-6 in the production of plasma proteins is different, but contributes to the pathways that are activated by 
other cytokines such as IL-1 and TNF-ocin the production of similar plasma proteins. IL-6 is also a co-
stimulator of T-cells and of thymocytes and is a co-factor, together with other cytokines, for the production 
of haematopoetic cells from the bone marrow and subsequent exercise-induced neutrophilia (Tilg et al., 
1994; Suzuki etal, 2002; Smith, 2000; Pedersen etal, 2001). 
Although Interleukin-6 has in the past been referred to as an "inflammatory" or "proinflammatory 
cytokine," the current trend is to classify it as an "inflammation-responsive" or anti-inflammatory 
cytokine rather than a pro-inflammatory cytokine, since IL6 does not directly induce inflammation , but 
reacts to it (Pedersen et al, 1998, Ostrowski et al, 1999; Steensberg et al, 2003; Peters, 2004). Smith 
(2003, 2004) suggests that increased levels of this cytokine in the circulation are also related to the 
systemic effects associated with over training syndrome (OTS). 
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It has been shown that contracting skeletal muscles produce large amounts of IL-6 and that muscle 
contractions per se are a stimulus for the production of muscle-derived IL-6. Many studies have revealed 
that IL-6 mRNA is markedly elevated in muscle biopsies carried out post exercise (Ullum et al., 1994; 
Ostrowski et al., 1998; Malm et al, 2000; Keller et al, 2001; Starkie et al, 2001; Steensberg et al, 
2001; Malm et al, 2004). The increase has been shown to be greatest when muscle mass recruitment is 
greatest. Treadmill running has therefore been found to elicit a greater release of IL-6 into the circulation 
than cycle ergometry. Circulating concentrations of IL-6 have been found to be considerably lower 
following downhill running than uphill running or running on a level terrain (Ostrowski et al, 1998b). 
In addition, it is also evident that in eccentric exercise the IL-6 kinetics differs greatly from that of 
concentric exercise as shown by Bruunsgaard et al. (1997). Therefore, in concentric exercise, the IL-6 
levels increase during exercise and decrease immediately after cessation of the exercise (Steensberg et 
al., 2001). In contrast, the modest, prolonged increase in IL-6 is found after eccentric exercise is likely to 
be a sign of repair mechanisms after muscle damage (Bruunsgaard et al., 1997). 
Many studies have demonstrated increased levels of IL-6 (up to 128 times) following bouts of severe 
eccentric exercise such as downhill and marathon running (Ostrowski et al, 1998b; 1999; Singh et al., 
1999, Nieman et al, 2001, Starkie et ai, 2001; Peters et al, 2001; Smith et al, 2007). These high levels 
are primarily attributed to the muscle damage associated with severe eccentric exercise (Pedersen and 
Hoffman-Goetz, 2000) and as a response to the subsequent activation of the pro-inflammatory cytokine 
cascade (Singh et al., 1999; Nieman et al., 2001; Pedersen, 2000; Pedersen and Hoffman-Goetz, 2000; 
Pedersen et ai, 2001). 
Table 2.4 Inflammatory response to endurance exercise longer than 2hr in duration with specific 
emphasis on IL-6 concentrations in venous blood 
Author/s 
Ostrowski et al.. 
1998B 
Ostrowski et al, 
1999 
Singh etal., 1999 






Suzuki et al, 2003 
Methodology 
16 male marathon runners, marathon 
race, mean: 3h, 17min 
10 male marathon runners, marathon 
race, mean: 3h, 27min 
10 female trained runners, Run, 65%-
70% max to exhaustion 
98 marathon runners, marathon race, 
mean: 3.8h 
29 runners, 90km marathon, 9-1 Oh 
5 male runners, marathon race, 2h-
31min-3h 25min 
10 male endurance athletes, 42 km 
marathon 
Results/Changes 
63 times | (Post), 15 times t 
(Post 2h) 
128 times but gradually 
declined thereafter 
80% t (During 30min), 5 times 
| (during 60 min), 7 times t 
(during 90 min), 11 times 
(Post), 10 times (Post lh), NC 
(post 24h) 
30 times | (Post), NC (post 
24h, 48h) 
25 times \ (Post), NC (Post 
24h and 48h) 
about 100 times \ (Post) but 
gradually declined thereafter 










2.2.4. Anti-Inflammatory Cytokines 
2.2.4.1. InterIeukin-10 (IL-10) 
Interleukin-10 (IL-10) is the most important anti-inflammatory cytokine within the human immune 
response. It is primarily synthesized by CD4+ Th2 cells, monocytes, and B cells and circulates as a 
homodimer consisting of two tightly packed 160-amino-acid proteins (Opal et al., 1998; Howard and 
O'Garra, 1992) After engaging its high-affinity 110-kd cellular receptor, IL-10 inhibits 
monocyte/macrophage-derived TNF-a, IL-1, IL-6, IL-8, IL-12, granulocyte colony-stimulating factor, 
MIP-la,andMIP-2oc(Clarkee?a/., 1998; Gerard et al., 1993; Marchant et al., 1994). 
It is also sometimes known as human cytokine synthesis inhibitory factor (CSEF) as it is identical to this 
factor and has the same function viz. it inhibits the synthesis of a number of cytokines such as IFN-y, IL2 
and TNF-p in the Thl subpopulations of T-cells (Fiorentino et al., 1989; Howard and O'Garra, 1992). IL-
10 is secreted by Th2 cells, targets B cells and macrophages. It is stimulatory towards certain T cells, mast 
cells and B cells. It inhibits the synthesis of pro-inflammatory cytokines like INF-y, IL-2, EL-3, and TNF-a 
which are secreted by macrophages and Thl cells. IL-10 also suppresses the antigen presentation capacity 
of macrophages and lymphocytes and is released by cytotoxic T-cells to inhibit the actions of NK cells in 
response to viral infection (Suzuki et al., 1999; Smith, 2000; Bagby et al., 1996; Peters, 2004; Pedersen 
and Hoffman-Goetz, 2000; Trinchieri, 2007). 
IL-10 inhibits cell surface expression of major histocompatibility complex class II molecules, B7 
accessory molecules, and the lippolysaccharide (LPS) recognition and signaling molecule CD 14 (Opal et 
al., 1998). It also inhibits nuclear factor kappa-B (NF-K-B) translocation after LPS stimulation (Brandtzaeg 
et al., 1996; Clarke et al., 1998) and promotes degradation of messenger RNA for the proinflammatory 
cytokines (Opal et al., 1998). In addition to these activities, IL-10 attenuates surface expression of TNF 
receptors and promotes the shedding of TNF receptors into the systemic circulation (Dickensheets et al., 
1997; Joyce etai, 1994). 
Studies have reported between 27 to 100 fold increases in plasma IL-10 following exhaustive endurance 
exercise (Ostrowski et al., 1999; Nieman et al., 2000, Peters et al., 2001b, Suzuki et al., 2003). Suzuki et 
al. (2003) also confirmed a positive correlation between the percentage increase of IL—6 (80 fold) and IL-
10 (100 fold) following participation in a competitive marathon race by 10 male endurance trained athletes 
between the ages of 16 and 19 years (r = 0.78, p < 0.01). This supports previous findings of the induction 
of IL-10 by the production of BL-6 (Nieman et al, 2003; Steensburg et al, 2001; 2003; Pedersen et al., 
2003). 
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Others have reported no increase in plasma IL-10 levels following short durations of high intensity 
exercise (Bruunsgaard et al., 1997; Smith et al., 2000; 2007). These findings suggest that high intensity 
exercise of extended durations only, may induce the release of IL-10 into the circulation (Suzuki et al., 
2002; Smith et al., 2007). 
2.2.4.2. Interleukin 1-Receptor Antagonist (ILl-ra) 
ILl-ra is, as its name suggests, is a polypeptide receptor antagonist that is secreted by macrophages, TH2 
cells and monocytes (Arend, 1993, 2000; Dinarello, 1994). It competes with ILl-a and ILl-(3 for the 
same receptor on the cell membrane. This is the only known function of ILl-ra (Hirsch et al., 1996; 
Arend, 2000). It was initially called IL-inhibitor after its discovery in 1984. As a result of it binding to 
the same receptor on the cell membrane as the IL1 family of interleukins, it prevents these cytokines 
form signaling the cell (Dinarello, 1994). It is thus used in the treatment of autoimmune diseases like, 
rheumatoid arthritis where the role of IL1 is significant in the pathophysiology of the disease. ILl-ra has 
been reported to be much more similar in structure to ILl-p" than it is to ILl-fX Four protein isoforms of 
ILl-ra have been reported, three of which are intracellular and one is a secreted from. However, all three 
have the same affinity for the IL1 receptor on the cell membrane (Arend, 1993; 2000; Muzio et al., 
1995). As previously mentioned, the interleukin-1 cytokines are pro-inflammatory in nature. Therefore, 
ILl-ra will have an antagonistic effect on their function. Thus the balance between ILl-a, ELl-p and 
ILl-ra dictates the dampening or progression of an inflammatory reaction. (Dinarello, 1994; Hirsch et 
al., 1996; Arend, 2000, Suzuki et al., 2000, Suzuki et al., 2002). 
Several studies have demonstrated elevated levels of ILl-ra following exhaustive exercise. These levels 
range from between 20 fold increases (Peters et al., 2001b) to 40 fold (Toft et al, 2000) and even 214 
fold (Suzuki et al., 2002). The different levels reported have been postulated to be due to different 
exercise workloads and differing assay techniques (Suzuki et al., 2002). Endurance exercise in itself has 
also been reported to cause an elevation in ILl-ra levels in several studies (Ostrowski et al., 1999; 2000; 
Pedersen et al, 2001, Peters et al, 2001b; Toft et al., 2002, Steensberg et al., 2003; Peake et al., 2005b). 
2.2.5. Chemokines 
2.2.5.1. Interleukin-8 
Interleukin-8 (IL-8) is a chemokine that is produced by muscles, macrophages, endothelial cells and some 
epithelial cells. Endothelial cells that produce IL-8 store the cytokine in storage vesicles called Weibel-
Palade bodies (Utgaard et al, 1998; Wolff et al, 1998). Upon encountering an antigen, macrophages 
release IL-8 which attracts neutrophils which adhere to and diapadese through the vascular endothelial 
cells to the region of inflammation (chemotaxis; Utgaard et al., 1998). IL-8 is therefore sometimes referred 
to as a Neutrophil Chemotactic Factor (NCF) or Neutrophil Activating Peptide 1 (NAP-1). It has also been 
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shown to display chemotactic activity for basophils, eosinophils and T-lymphocytes (Kishimoto et al, 
1995; Van der Poll et al, 1997; Febbraio and Pedersen, 2005; Juge-Aubry et al, 2005). 
Some studies have revealed a slight increase in IL-8 levels in the blood following exercise of a moderate 
intensity (Henson et al., 2000; Suzuki et al., 2002). However, following intense periods of exhaustive 
exercise, IL-8 levels have been shown to be significantly elevated in the blood (Nieman et al., 2000; 
Suzuki et al, 2000; Nieman et al, 2001; Ostrowski et al, 2001; Peters et al, 2005; Smith et al, 2007). 
Peters et al. (2005) reported increases from 3.7 to 30.2 pg/ml following a downhill ultra-marathon race. It 
has also been demonstrated that severe exercise for a short duration causes the release of IL-8 into the 
circulation (Mucci et al, 2000; Suzuki et al, 2002; Smith et al, 2007). 
2.2.6. Immunomodulatory Cytokines 
2.2.6.1. Interleukin-12 
Interleukin-12 (IL-12) is secreted by B-cells and macrophages (Ganong, 2005) and refers to a collection of 
IL-12 related proteins. The bioactive form of IL-12 is a 75 kDa heterodimer (IL12p70) comprising 
independently-regulated disulfide-linked 40 kDa (p40) and 35 kDa (p35) subunits. The p40 subunit exists 
extracellularly as a monomer (IL12p40 1) or dimer (IL-12p40 2) and can antagonize the action of IL12p70 
(Bagby et al, 1996; Suzuki et al, 1999; Smith, 2000; Pedersen and Hoffman-Goetz, 2000; Kalihski et al, 
2001). 
In conjunction with the action of other cytokines (IL-2, in particular), interleukin-12 helps to activate 
cytotoxic T-cells. It also stimulates the proliferation of NK cells and Thl cells and is involved in the 
differentiation of immature T cells into Thl cells. It is therefore sometimes referred to as a T cell 
stimulating factor. It also assists in the stimulation and production of interferon-gamma (IFN-y) and tumor 
necrosis factor-alpha (TNF-a) which are produced by Thl cells and NK cells. IL-12 helps to reduce the 
suppression of IFN-y which is controlled by IL-4. IL-12 displays anti-angiogenic activity (suppression of 
new blood vessel production). This is achieved by it increasing the production of IFN-y, which in turn, 
stimulates the production of a chemokine called inducible protein-10 (IP-10 or CXCL10). EP-10 mediates 
the anti-angiogenic effect (Pedersen and Hoffman-Goetz, 2000; Kaliriski et al, 2001). 
There is conflicting evidence in the literature regarding the effects of exercise on the levels of circulating 
IL-12 in the blood. For example, some studies reported increased levels following high intensity exercise 
with heat exposure, while no elevation in the absence of heat exposure has also been reported (Akimoto et 
al, 2000; Peake et al, 2005a; 2005b). 
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While inconsistencies and lack of reproducibility have been attributed to the rapid down-regulation of IL-
12 levels following exercise and also to different measurement methods and ELIZA kits employed 
(Akimoto et al., 2000; Suzuki et al, 2002), Suzuki et al. (2003) have more recently differentiated between 
the response of IL-12p40 and IL-12p70. They reported that following a marathon race in which plasma 
concentration of IL-6 increased by 80 fold and IL-10 by 100 fold, cytokines promoting cellular immunity 
including IL-2, IFN-y, TNF-cc and IL-12p70 did not rise. IL-12p40, however, increased markedly. In 
contrast, an incremental exercise test to exhaustion on a treadmill did not result in an elevation in the IL-
12p70 or IL-12p40 content of venous blood immediately after the exercise test when values were adjusted 
for hemoconcentration and plasma volume changes (Suzuki et al., 2003). One hour post-test IL-12p40 
concentrations, however, did increase significantly from 46.1 pg/ml to 72.9 pg/ml (p < 0.01), but IL-12p70 
remained unchanged. Suzuki et al. (2003) propose that the increase in the production of IL-12p40 and 
cytokines mediating inflammation is the result of exercise-induced release of prostaglandin E2, cAMP, 6-
adrenergic agents and histamine. 
2.2.7. Pro and Anti-inflammatory Cytokine Response to Eccentric Endurance Exercise 
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Figure 2.1: The Pro-Inflammatory cytokine cascade depicting the negative feedback mechanism 
In response to tissue microtrauma which occurs following eccentric exercise, macrophages which are 
resident in the injured tissue, become activated, releasing TNF-°= which has been shown to activate a pro-
inflammatory cytokine cascade with the subsequent release of IL - 1 (3 and I L - 6 (Figure 2.1; Suzuki et al., 
1999; Suzuki et al., 2000; Pedersen et al, 2001). Increased circulating concentrations of IL - 6, in turn, 
stimulate the adrenal medulla to increase its release of Cortisol into the blood stream which stimulates the 
release of a number of compensatory anti-inflammatory cytokines, such as IL - 10 and IL -1 receptor 
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antagonists (Figure 2.1; Pedersen and Hoffman-Goetz, 2000). These play a crucial role in containment and 
isolation of the inflammatory process (Bagby et al., 1996; Peters, 2004). 
While the presence of multiple cytokines (TNF-a, ILl-fi, IL-6, IL-2 receptors, and IFN-g) in urine after 
exercise reflects the expression of a broad spectrum of cytokines in response to exercise (Sprenger et ai, 
1992), Pedersen et al. (1998) suggest that the type of physical activity as well as the intensity and 
duration of the exercise may affect the concentrations of pro-inflammatory cytokines measured in the 
blood. In reviewing the findings in the literature regarding the pro-inflammatory cytokine response to 
endurance exercise longer than 2 hr (Table 2), Ostrowski et a/.(1998), Ostrowski et al.{ 1999a), Singh et 
a/.(1999), Nieman et a/.(2000), Starkie et al.(2001) and Peters et a/.(2001) showed that after a marathon 
race, TNF-a and IL - lp concentrations in the vascular department increased by a maximum of 
approximately 4.3-fold (Starkie et al, 2001), whereas the concentrations of IL-6 increased by as much as 
128 fold (Ostrowski et al., 1999). As both concentrations of IL-10 and IL-lra, however, increase 
substantially following prolonged eccentric exercise (Nieman et al., 2001; Peters et al, 2001b), it has 
been suggested that the relatively lesser increment in TNF and IL-1 concentrations in the blood is due to 
the release of cytokine inhibitors including [IL-lra and TNF receptors (TNF-R)] and the anti-
inflammatory cytokine IL-10 (Ostrowski et al., 1999b; Figure 2.1). These findings suggest that cytokine 
inhibitors and anti-inflammatory cytokines may restrict the magnitude and duration of the pro-
inflammatory response to exercise. 
2.3. The Thl - Th2 Differentiation; Corresponding Cytokine Production And its Effects. 
2.3.1. Introduction 
Although cytokines are produced by a variety of cells including the vascular endothelium, macrophages 
and circulating leukocytes, cytokines produced by helper T-cells are special subpopulations that provide 
help to other cells of the immune system in mounting immune responses. 
According to Morel and Oriss (1998), the CD4 T helper (Th) and the CD8 T cytotoxic (Tc) cells can be 
divided into type 1 (Thl and Tel) and type 2 (Th2 and Tc2) cells according to their cytokine profile. Thl 
cells drive cellular immunity and produce IL-2, TNF-a and interferon-gamma (INF- IFN- y), while Th2 
cells that activate the humoral response, produce a variety of anti-inflammatory cytokines, including IL-4, 
IL-5, IL-6, IL-10, and IL-13 (Evans et al., 2000). Type 1 immunity, also referred to as cell mediated 
immunity, involves macrophage activation and the recruitment and stimulation of cytotoxic cells such as 
Tc-cells and NK cells. This is stimulated by and effective against intracellular pathogens such as viruses 
and various intracellular bacteria, including tuberculosis bacilli (Evans et al., 2000; Romagnani, 2000). In 
contrast, extracellular pathogens, like helminthic (worm) parasites, and most forms of bacteria stimulate 
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Type 2 immunity which involves the humoral immune response and the production of most types 
(isotypes) of antibodies. 
The balance of both types of T-helper cells can be influenced and regulated by the very cytokines they 
secrete. For example, IFN- y, secreted by Thl cells, can inhibit the proliferation of Th2 cells, while EL 10, 
secreted by Th2 cells, can suppress Thl functions by inhibiting their cytokine production. The Th2 
cytokine IL-4, inhibits the differentiation and/or expansion of Thl cells. Therefore, the functional subsets 
of T-helper cells are mutually antagonistic such that the predomination of a subset within an infection, may 
determine its outcome (Mackay, 2001; Romagnani, 2000; Kelso et ai, 1991). 
Through the activities of the types of cytokines produced, Thl and Th2 cells are able to cross regulate 
each other. This control mechanism helps prevent the inflammatory reactions in response to pathogens, 
getting out of control. However, it is also possible that imbalances may precipitate inappropriate reactions. 
It is postulated that some autoimmune disorders may involve overactive Thl cells, while the exacerbation 
of other conditions such as allergies, may involve overactive Th2 responses (Romagnani, 2000; Bonecchi 
etai, 1998 Smith, 2003; 2004). 
The molecular mechanisms by which the evolution of these different T-helper cell types occurs from 
common precursors, are still not completely understood. Thp cells (p for precursor) are believed to be the 
precursor cells of ThO cells that, in turn, are thought to be precursor cells that develop into either Thl or 
Th2 cells (Romagnani, 2000; Kelso etal., 1991). 
While Thl cells are responsible for stimulating strong cellular immunity, they only activate weak and 
transient antibody responses. Generally, Thl responses are stimulated by intracellular pathogens (viruses, 
some mycobacteria, some yeasts, and some parasitic protozoans) and by IL-12 (Lucey et ai, 1996). Thl-
type cells secrete high levels of IL-2, TNF-a, and IFN- y. This activates macrophages and promotes cell-
mediated immune responses against invasive intracellular pathogens (Bonecchi et ai, 1998; Romagnani, 
2000). 
On the other hand, chronic stress states have been found to skew the balance against type 1 immunity in 
favour of type 2 immunity (Elenkov and Chrousos, 1999; Evans et ai, 2000; Romagnani, 2000). In 
particular, IL-6 has been shown to induce Th2 polarization by stimulating the initial production of IL-4. 
More recently a third category of Th-cell has been identified. Th3 cells are CD4 (+) regulatory cells 
associated with immune mechanisms involving oral tolerance towards antigens. These cells are 
characterised by the secretion of TGF-P and they have suppressive properties for Thl and Th2 cells 
(Mosmann and Coffman, 1989; Bonecchi et al., 1998; Romagnani, 2000). The pleiotropic anti-
inflammatory growth factor transforming growth factor-bl (TGF-bl) belongs to a family of growth factors 
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that has diverse effects on cellular differentiation, activation, and proliferation. It has also been shown to 
act as a chemoattractant for monocytes and macrophages and to inhibit the cells required for the 
inflammatory process. It is therefore regarded as an anti-inflammatory cytokine that aids in wound healing 
by limiting the inflammatory response (Bonecchi et al., 1998; Elenkov and Chrousos, 1999). 
2.3.2 Regulation of the Thl - Th2 Differentiation 
Little is currently known about the physiological regulation of type 1 and type 2 T cell balances. It has 
been suggested that exercise is an appropriate model to study how the type 1 and type 2 cell balances are 
regulated. Both Cortisol and epinephrine have been found to inhibit the production of type 1 T cell 
cytokines (Franchimont et al, 2000). Regulation of T-cell activation by the anti-inflammatory cytokines is 
also a crucial early control element in this process (Romagnani, 2000). 
Interleukin-4 (IL-4) is a highly pleiotropic cytokine that is able to influence Th cell differentiation. It is a 
20-kd glycoprotein produced by mature Th2 cells and cells from the mast cell or basophil lineage. It drives 
Th2 responses, mediates the recruitment and activation of mast cells, and stimulates the production of IgE 
antibodies via the differentiation of B cells into IgE-secreting cells (Mosmann et al., 1986; Kelso, 1995). 
Early secretion of EL-4 leads to polarization of Th cell differentiation toward Th2-like cells (Mosmann et 
al., 1986). Th2-type cells secrete their own IL-4, and subsequent autocrine production of IL-4 supports 
Th2 cell proliferation. The Th2- cell secretion of IL-4 and IL-10 also leads to the suppression of Thl 
responses by down-regulating the production of macrophage-derived IL-12 and inhibiting the 
differentiation of Thl-type cells (Mosmann et al., 1986; Kelso, 1995). 
IL-10 is also a potent inhibitor of Thl cytokines, including both IL-2 and IFN-y. This activity accounts for 
its initial designation as cytokine synthesis inhibition factor (Opal et ah, 1998; Lalani et al., 1997; Howard 
and O'Garra, 1992) In addition to its activity as a Th2 lymphocyte cytokine, IL-10 is also a potent 
deactivator of monocyte/macrophage proinflammatory cytokine synthesis (Clarke et al., 1998). 
2.3.3. The Thl - Th2 Shift Effect During Exercise 
To further understand how the type 1 and type 2 T cell balances are regulated, it is of interest to investigate 
the effect of exercise. As viruses often cause URTI and type 1 T cells are crucial in the defense against 
intracellular pathogens (Steensberg et al, 2001), the observation of an increased risk of URTI after an 
acute bout of heavy exercise, may be a consequence of an impaired type 1 T cell response (Smith, 2000). 
It has been shown that the immune response to strenuous exercise has some similarities to that of other 
physical stress conditions such as surgery, trauma, sepsis, and burn (Pedersen and Hoffman-Goetz, 2000; 
Smith, 2003; 2004). Interestingly, it has recently been demonstrated that major surgery suppresses 
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maximal production of Thl cytokines without influencing the Th2 cytokines (Berguer et al., 1999), 
inferring that surgery and strenuous exercise influence the Thl and Th2 responses in a similar manner. 
Figure 2.2: The effect of prolonged exercise on the Thl-Th2 cytokine balance following 
exhaustive exercise 
During intense and prolonged exercise, lymphocytes are recruited to the blood (Pedersen and Hoffman-
Goetz, 2000). However, in the post-exercise period, the number of circulating lymphocytes declines below 
pre-exercise values. Concomitantly, the plasma levels of proinflammatory cytokines are elevated. Thus the 
level of plasma IL-6 may be enhanced more than 100-fold (Ostrowski et al, 1999), but increases in plasma 
IL-12 have been reported to be inconsistent and small (Akimoto et al., 2000). 
The greatest elevations in inflammation-mediated cytokine levels have been reported after eccentric 
exercise. Bruunsgaard et al. (1997) compared concentric and eccentric exercise at the same relative 
oxygen uptake. They found that although the catecholamine levels did not differ between the two 
experiments, the creatine kinase (CK) increased almost 40-fold 4 days after eccentric exercise. No changes 
were observed in the CK concentration in relation to concentric exercise. The IL-6 concentration increased 
fivefold in relation to eccentric exercise and was significantly correlated with the CK concentration in the 
subsequent days; no changes were found, however, in relation to eccentric exercise. This study indicates 
that there was an association between increased IL-6 concentration and muscle damage, but it remains to 
be shown whether the relationship is causal or not. 
Steensberg et al. (2001) reported that the percentage of circulating type 1 T cells decreased after prolonged 
exercise, whereas the percentage of type 2 T cells did not change, and concomitantly the total number of 
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circulating T cells declined. Moreover, the post-exercise decrease in circulating T lymphocytes is 
accompanied by a more pronounced decrease in the type 1 T cell subpopulation. 
Plasma IL-2 and IFN-y have not been shown to rise following intensive short term or prolonged endurance 
exercise. In vitro studies have shown that acute exercise impairs the ability of stimulated lymphocytes to 
produce IL-2 (Northoft et al., 1998; Rhind et al, 1996; Steensberg et al., 2001, 2003) a response which is 
reversed with administration of indomethacin suggesting the involvement of prostaglandins. Suzuki et al. 
(2003), however, suggest that exercise-induced release of soluble IL-2 receptor which interferes with the 
measurement may also be a factor contributing to the failure to detect IL-2 in the blood of exercising 
athletes. 
Both animal and human studies, in vivo and in vitro, have revealed that T cells producing IFN-y and IL-2 
are suppressed by Cortisol and epinephrine (Elenkov and Chrousos, 1999; Franchimont et al., 2000). These 
hormones increase during and in response to exercise. Cortisol is thought to operate by inhibiting the 
production of IL-12 by antigen-presenting cells (Elenkov and Chrousos, 1999) and also by decreasing the 
ability of T cells to respond to IL-12 (Franchimont et al.,2000). Epinephrine also suppresses the type 1 T 
cells both at the level of antigen-presenting cells and directly on T cell receptors. Steensberg et al. (2000) 
found a negative correlation between mean plasma epinephrine and percentage of IL-2-producing CD8 
Type 1 cells. These cells express more 62-adreno-receptors on the surface compared with Thl cells 
(Pedersen and Hoffman-Goetz, 2000) which may explain that only the percentage of type 1 T cells 
correlated with epinephrine during exercise (Steensberg et al., (2000) study. No evidence of Cortisol 
correlation with type 1 T cells was found. 
Rincon et al. (1997) demonstrated that IL-6 stimulates the production of IL-4 by naive CD4 Type-1 T-cells 
as plasma IL-6 increases enormously in response to exercise (Ostrowski et al., 1999) and that contracting 
skeletal muscles release IL-6 (Steensberg et al, 2000). However, exercise induced increases in circulating 
IL-4-have not been reported. The correlation between plasma IL-6 and percentage of IL-4-producing CD8 
Type-1 T-cells may however indicate that the increase in plasma IL-6 during exercise contributes to 
maintaining an unaltered percentage of Type 2 T-cells and, thereby, influences the balance between the 
Type-1 and Type-2 T-cells. During exercise, muscle glycogen is reduced. This contributes to enhancing 
the production of IL-6 and, thereby, the effect of IL-6 on Cortisol secretion (Peters, 2004). Furthermore, the 
level of catecholamines in plasma increases more when subjects exercise under fasting conditions. Thus 
exercising in a carbohydrate-loaded state might have induced a less pronounced effect on the type 1 or 
type 2 T cell balance (Steensberg et al, 2000). 
Steensberg et al. (2000) postulated that IL-6 probably functions through the HPA axis thereby increasing 
secretion of Cortisol. In accordance, their study demonstrated a correlation between peak plasma IL-6 and 
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plasma Cortisol 1 h post-running (Steensberg et al., 2000). The relatively more pronounced decrease in 
type 1 compared with type 2 T cells in the recovery period may explain the increased sensitivity to URTI 
following strenuous exercise, as these infections are often caused by viruses. 
2.3.4. The Role of Cortisol 
The influence of the stress hormone, Cortisol, often incorrectly referred to as an immunosuppressant 
hormone, on the function of the immune system is complex. However, under normal circumstances and in 
physiological amounts, Cortisol tends to shift the immunological balance away from Thl mediated and 
towards Th2 mediated immunity. This has been demonstrated in numerous studies (Agarwal and Marshall, 
1998; Visser et al., 1998; Smith, 2003; 2004). 
In psychological stress there is a shift in the balance of the immune system away from Thl activity, which 
is usually associated with increased Cortisol levels and can be reversed with Cortisol receptor antagonists 
(Evans et al., 2000; Glaser et al., 1994). The catecholamine stress hormones are also thought to be 
important in this respect with similar evidence implicating a2-adrenergic receptors on immune cells 
(Elenkov and Chrousos, 1999). 
In parallel, in addition to the previously described rise in circulating Cortisol concentrations occurring 
during and immediately following acute exercise exposure, long-term endurance training results in 
immunological changes associated with increased blood Cortisol levels and increase in the Cortisol/ 
androgen ratio (both the adrenal androgen - DHEA and gonadal androgen / testosterone) (Bernton et al., 
1995, Suzuki et al., 2000; Smith, 2003; 2004). Similarly, these immunological changes are most easily 
described in terms of a shift in the balance of the immune system away from type 1 and towards type 2 
immunity. This stress hormone-induced shift away from type-1 towards type-2 immunity has been shown 
to increase susceptibility to infection as well as duration of an infection once established (Elenkov and 
Chrousos, 1999). Athletic injury, the progression of which is itself subject to the consequences of reduced 
type 1 immunity (increasing the possibility of infection) also contributes to the immunological shift in 
immunity towards type 2 via production of Th2 cytokines triggered by activation of the sympathetic 
branch of the ANS (Elenkov and Chrousos, 1999; Smith, 2003; 2004). 
Fairly consistently, Cortisol- induced down-regulation of salivary IgA defence of mucosal surfaces and 
increased susceptibility to mucosal infections such as upper respiratory tract infection has also been 
demonstrated (Gleeson et al., 1999; Pedersen and Hoffman-Goetz, 2000; Pedersen et al., 2001). Thus the 
similarity between the effects of the physical and psychological stress on the immune system indicate that 
the summative effects of both types of stress are cumulative and synergistic and point to competitive 
athletes as a particularly vulnerable population with which very effort must be made to reduce the negative 
impact of both types of stressors. Indeed there is convincing evidence that elite athletes are more 
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vulnerable to opportunistic infectious illness (Peters and Bateman, 1983; Gleeson, 2000; Mackinnon, 
1997; Pedersen etal, 2001; Smith, 2003; 2004). 
The rise in serum Cortisol concentration following prolonged exercise is well documented (Peters, 2001a; 
2001b). Post-exercise concentrations have been shown to rise by more than 50% following 60 minutes of 
downhill treadmill running (gradient -13.5%) at 75% V02max (Smith et al., personal correspondence), but 
± 200% increases to pm values of 1040 ± 113 (Peters et al., 2001a) and 1179 ± 93.2 mmol/ L (Peters et al., 
2001b) have been reported following a 90km downhill ultra marathon run despite considerably lowered 
diurnal Cortisol variations in the late afternoon post-race blood samples. 
The exercise-induced rise in systemic Cortisol concentration is a sequel to the stimulation of the HPA axis 
and adrenal cortex by IL-6 and increased concentration of circulating Cortisol have been reported to and on 
bone marrow, causing a further release of neutrophils into the blood stream (Starsky et al., 2003; Pedersen 
and Hoffman-Goetz, 2000; Suzuki et al., 1999). Due to the anti-inflammatory properties of Cortisol, which 
activates the production of anti-inflammatory polypeptides including EL-10 and IL-lra (Peters, 2001b), 
inflammation has been theorized to be restrained once Cortisol concentrations reach a critical level and the 
body is given the opportunity to repair the tissue (Van Brandt, 2002). 
2.4. The Repeated Bout Effect 
The repeated bout effect is described as the adaptation of muscle where a single bout of eccentric exercise 
protects against muscle damage from subsequent eccentric bouts (McHugh et al., 1999; McHugh, 2003). 
The mechanisms responsible for this adaptation are poorly understood and are a subject of active study in 
the literature. Despite numerous studies that have clearly demonstrated the repeated bout effect, little 
consensus exist as to the actual mechanism. Recently, significant advances in the understanding of the 
repeated bout effect phenomenon have been reported in the literature (Hortobagyi et al., (1997, 1998, 
Lavendera and Nosaka, 2008). 
The mechanisms are attributed to neural, connective tissue or cellular adaptations (McHugh et al., 1999). 
Other possible mechanisms include the adaptation in the excitation-contraction coupling mechanism of 
muscle or adaptation in the inflammatory response following the initial bout of exercise (McHugh et al., 
1999; McHugh, 2003, Lavendera and Nosaka, 2008). There has been evidence to suggest that the repeated 
bout effect is associated with a shift toward greater recruitment of slow twitch motor units (McHugh et al., 
1999; McHugh, 2003, Lavendera and Nosaka, 2008). 
The neural theory refers to the pattern of recruitment of muscle fibres. It suggests that the change in the 
pattern of motor unit recruitment intra muscularly results in a reduction in the muscle damage during 
subsequent sessions of eccentric exercise (Golden and Dudley, 1992). In a similar study carried out by 
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Hortobagyi et al, (1998) an increase in muscular strength following repeated bouts of exercise was 
reported. Hortobagyi et al. (1998) concluded that an improved distribution of workload among muscle 
fibres in the subsequent bouts of exercise occurred and this could be explained by an altered pattern of 
motor -unit recruitment. 
The connective tissue theory predicts that after the first bout of eccentric exercise, the muscles are 
protected by an overall increase in intramuscular connective tissue (Frieden and Lieber, 1992; McHugh et 
al., 1999; Frieden and Lieber, 2001; McHugh, 2003). The increase in connective tissue content is thought 
to be provided by the intermediate filaments within the muscle fibre, which consist of proteins, desmin, 
vimentin and synemin. These filaments play a role in maintaining the structural integrity of the sarcomere 
through preserving the sarcomere stretch and overlap during eccentric exercise (Frieden & Lieber, 1992). 
The non-contractile proteins are thought to be directly involved in the remodelling process of 
myofilaments disrupted during eccentric contractions. During this process, the muscle-tendon complex is 
thought to adapt its viscoelastic properties to enable it to absorb and transmit the forces produced during 
sudden and forceful contractions (Yu et al., 2003a; 2003b). 
McHugh et al. (1999) explain that cellular theory proposes that muscle damage occurs as a result of 
irreversible sarcomere strain during eccentric contractions. Due to the nature of eccentric exercise during 
which muscles are lengthened while contracting, sarcomere lengths are highly non-uniform during these 
types of contractions (Frieden and Lieber, 1992; Hortobagyi et al, 1998; Frieden and Lieber, 2001). Some 
sarcomeres are stretched beyond the limit of myofilament overlap. The loss of contractile integrity results 
in sarcomere strain and is seen as the initial stage of damage (McHugh et al., 1999, Yu et al., 2003a, Yu et 
al., 2003b). Some data suggest that an increase in the number of sarcomeres connected in series, following 
an initial bout, reduces sarcomere strain during a repeated bout and limits the subsequent damage 
(Hortobagyi etal, (1998, 1999). 
Multiple mechanisms therefore appear to be responsible for the repeated bout effect. Although significant 
advances have been made in understanding the adaptations seen in muscle tissue after the initial bout of 
eccentric exercise, a comprehensive unified theory describing all the components involved, remains 
elusive (Hortobagyi etal., 1998; McHugh etal., 1999). 
2.5. The Effect of Traumeel On Inflammatory Markers in the Blood 
According to Schroder et al.(1990) the blossoms of Arnica montana have been used for therapeutical 
purposes because of their antiphlogistic and analgesic effects. More than 150 chemical substances have 
been found in Arnica blossoms and, among these, helenalin and its derivatives and flavonoids are the most 
important. In vitro and in vivo studies have shown the anti-inflammatory and anti-microbial activity of 
these substances (Kubo et al, 1994; Lyss et al, 1997). Homeopathic preparations of Arnica montana, 
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often used in combination with other drugs, were reported to have therapeutic effects in conditions like 
traumas, childbirth, haematomas, dental pain (Gibson et al, 1991; Ventoskovskij and Popov, 1990). A 
preparation containing active principles from Arnica montana together with other plant extracts and 
minerals, that could potentially act in synergistic way, has been developed by Heel GmbH and called is 
called Traumeel®S. 
Traumeel®S (Traumeel), a mixture of highly diluted (lO'-lO9) extracts from medicinal plants and 
minerals is widely used in humans to relieve trauma, inflammation and degenerative processes. However, 
little is known about its possible effects on the behaviour of immune cells (Porozov et ai, 2004). 
Lussignoli et ai, 1999 report that the anti-inflammatory effect of Traumeel®S is presumably the result of 
the activity of single components on the different phases of inflammation. They cite the Handbook Materia 
Medica, Heel GmbH (1992) which suggests that Aconitum, Chamomilla, Hamamelis and Hypericum may 
reduce the pain associated with inflammation; Aconitum, Arnica, Hamamelis, Hypericum, Millefolium may 
have anti-hemorrhagic effects; Arnica, Calendula, Echinacea, Symphytummay accelerate the wound 
healing; Mercurius solubilis may be a anti-inflammatory and anti-viral agent, Hamamelis may prevent the 
venous stasis; Hepar sulfuris may improve the cellular breathing. The main indications of Traumeel®S are 
referred to different types of lesions and inflammatory processes involving muscles and joints, sprains and 
bruises. Its efficacy has been demonstrated in experimental and clinical studies, even under placebo-
controlled trials (Zell et ai, 1989; Bohmer and Ambrus, 1992). However, the mechanism by which this 
drug exerts its therapeutic effects remains to be clarified (Lussignoli et ai, 1999). 
Conforti et al. (1997) tested Traumeel®S in vivo on acute and chronic experimental inflammatory 
conditions on rats caused by intra-paw injection of carrageenan (carrageenan oedema) or Freund's 
complete adjuvant (adjuvant arthritis). The results of their study suggested that the local administration of 
Traumeel®S reduced oedema development and this inhibition was similar to the effect exerted by aspirin at 
dose of 30 mg/Kg in the same experimental model. In an adjuvant arthritis model, the intra-paw 
administration of Traumeel®S every two days led to a significant reduction in acute local inflammation, 
without affecting the chronic arthritic process (Conforti et al., 1997). 
Lussignoli et al. (1999) reported a series of experiments aimed to improve the knowledge of the 
therapeutic action of Traumeel®S by using an injection intra-paw of a small amount of homologous blood 
that mimics a traumatic blood extravasation, a condition usually treated with Traumeel®S. They also tested 
the activity of individual components of Traumeel®S on blood-oedema and of a combination containing 
only the components with known anti-inflammatory activity. Their preliminary data also indicated a 
possible role of IL-6 in the Traumeel®S regulation of the inflammatory process, but due to the complex 
nature of the cytokine network, further work is necessary to clarify this point. Lussignoli et al. (1999) 
concluded that it is possible that Traumeel®S accelerates the tissue changes involved both in the formation 
and in the elimination of oedema, with a net beneficial effect on the overall reaction. 
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Porozov et al. (2004) conducted a study in which effects of Traumeel S were examined in vitro on the 
ability of resting and PHA-, PMA- or TNF-a-activated human T cells, monocytes, and gut epithelial cells 
to secrete the LL-ip, TNF-a and IL-8 over a period of 24-72 hours . While they found that Traumeel®S did 
not affect T cell and monocyte proliferation, Traumeel®S, however, inhibited the secretion of all three 
cytokines in resting, as well as activated immune cells. IL-P secretion was reduced by up to 70% in both 
resting and activated cells, TNF-a secretion was reduced by up to 65 and 54%, respectively, and IL-8 
secretion was reduced by 50% in both resting and activated cells (p < 0.01 for all cells). Interestingly, the 
effect also appeared to be inversely dose-related; maximal inhibition (usually 30-60% inhibition; P<0.01) 
was seen with dilutions of 10"3 - 10"6 of the Traumeel®S stock material. This suggests that Traumeel®S 
does not inhibit immune cells functions by exerting a toxic effect. 
Heine and Schmotz (1998) have also shown that in whole blood cultures, Traumeel®S had the effect of 
elevating levels of Transforming Growth Factor (TGF-p), a Th3 cytokine which suppresses Thl and Th2 
cell activity and has also been described as an anti-inflammatory cytokine (Mosmann and Coffman, 1989; 
Bonecchi et al., 1998; Romagnani, 2000, Table 2.1.). 
Although additional studies are needed to clarify the mode of action of Traumeel®S and to demonstrate 
causative relationship between the inhibition of pro-inflammatory cytokine/chemokine secretion in cell 
culture and the reported clinical effects of the preparation, this in vitro work of Porozov et al. (2004) and 
Heine and Schmotz (1998) does shed greater light on a possible mechanism for the anti-inflammatory 
effects of Traumeel®S observed in clinical use. 
While non-steroidal anti-inflammatory drugs act by inhibiting the arachidonic acid pathway and therefore 
the production of prostaglandins by means of inhibiting the cyclooxygenase and lipoxygenase enzymes 
(Lussignoli et al., 1999; Porozov et al., 2004, Ganong, 2005), Traumeel®S has, however, been shown to 
control the generation of reactive oxygen species (ROS) by activated neutrophils. Therefore with the 
ingestion of Traumeel, increased neutrophilic oxidative burst activity and lymphocyte function is possible 
as the suppressive action of high levels of ROS on the leucocytes would be neutralised by Traumeel®S 
(Conforti et al., 1997, Peters, 1997b). It is hence proposed that the inflammatory response is restrained 
despite stimulation of the innate and secondary adaptive responses to the tissue damage, a finding that is 
supported by the increased plasma myeloperoxidase concentrations most recently reported in another 
dimension of this, as yet, unpublished, experimental work (Smith, 2008). 
2.6. Traumeel® S and Exercise Induced Muscle Inflammation 
Although Traumeel®S is a widely used product, its effects on the immune system following endurance 
exercise have been published in very few reputable scientific journals. Zell et al. (1989) conducted a 
double-blinded, placebo-controlled trial in order to test the effect of Traumeel®S ointment on joint 
mobility and subjective ratings of pain after sports related ankle injury. In their study, Traumeel S 
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ointment was found to be significantly more effective than placebo in the reduction of pain and the 
improvement of joint range of motion 10 days following the injury. These findings were consistent with 
those of Bohmer and Ambrus (1992) and Wright-Carpenter et al. (2004) who reported improved recovery 
times for the injuries studied in their respective investigations when compared to placebo. 
In the first in vivo study conducted on athletes at the Sports Research Institute of Pretoria University 
(Jordaan, 2006), subjects taking Traumeel®S 7 days prior to a 45 minute downhill run at -10 %, displayed 
a significantly higher blood Cortisol response compared to the placebo group at 48hr, 72hrs and 96hr post 
exercise. The only markers relevant to a systemic inflammatory response were blood Cortisol, leukocyte 
counts and serum creatine kinase levels. Although subjective perceptions of delayed onset muscle soreness 
were also quantitated, post-exercise neutrophilia and statistically significant elevations in serum Cortisol 
and CK concentrations were not reported (Jordaan, 2006). It is therefore uncertain whether the exercise 
was intense enough to elicit an inflammatory response in this study. 
27. Conclusion 
In conclusion, exercise, especially that of a strenuous and/or eccentric nature, has been shown to have an 
inflammatory effect that generates a response analogous to the acute phase response. The pro-
inflammatory response to muscle damage and consequent soreness has been clearly demonstrated. 
Although Traumeel® S has been advocated to be effective in accelerating the recovery process and has 
been used by sportsmen for this purpose for a long time, most of the biochemical studies examining the 
possible mechanism of action, have been in vitro. The need for a comprehensive in vivo study on 
endurance athletes which includes a comprehensive analysis of systemic markers of inflammation, with 
specific reference to the cytokine milieu, therefore still exists and is an open area for future research. 
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Chapter Three 
Materials and Methods 
3.1. Study design, ethical approval and insurance 
This study was designed as a double-blinded, placebo-controlled clinical trial in which subjects were 
matched and randomised to Traumeel (TRAU) and Placebo (PLAC) pairs which ingested either Traumeel 
(TRAU) or Placebo (PLAC) for 9 days; 5 days before, the day of and 3 days after a 90-minute downhill 
running intervention. 
Ethical clearance was obtained from the University of KwaZulu-Natal (UKZN), Nelson R. Mandela 
School of Medicine, Biomedical Research Ethics Committee (Clearance Number: E017 05). Insurance was 
obtained from Heel (Pty) Ltd. in Germany, to cover the UKZN in the event of possible research-related 
injury to the participant. The subjects were recruited by word of mouth from various running clubs in the 
greater Durban area. Each subject signed an informed consent form which had been approved by the 
Biomedical Research Ethics Committee of the University of KwaZulu-Natal (Appendix A, B). 
3.2. Sample 
3.2.1. Size: The study subjects included 18 distance runners and 2 team sport players, matched according 
to gender, selected anthropometrical characteristics, training age and status, footstrike pattern and 
performance level and then randomised into TRAU (n = 10) and PLAC (n =10) groups. 
3.2.2. Inclusion criteria: These included volunteers who: 
o fell within the age category of 20 to 50 years inclusive 
o were asymptomatic 
o were healthy runners who covered a minimum of 40 km per week in training or who were 
training a minimum of three times per week if participating in team sports, during the six 
weeks prior to participation in the study 
o were not on any anti-inflammatory or analgesic medication, antioxidant supplements, free 
of systemic illness, not pregnant and were all non-smokers 
3.2.3. Exclusion criteria: Subjects who did not fulfil the inclusion criteria were automatically excluded. In 
addition, those subjects who were non compliant with respect to the methodology of the study were also 
excluded. These included subjects from whom blood samples were unobtainable, who misplaced the 
tablets, who became ill immediately prior to or post trial and those who did unaccustomed training before 
and/or after the trial. 
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3.3. Study Protocol 
Prior to the onset of the study, the subjects were required to undergo baseline laboratory and field testing. 
(Figure 3.1). The laboratory testing took place in the exercise laboratory in the Department of Physiology 
at the Nelson Mandela School of Medicine and included assessment of the anthropometrical 
characteristics, lung function and V02peak of the subject, while the field test included a 1609 m time-trial 
on an athletics track. 
Thereafter each of the subjects was matched according to gender, physical and performance 
characteristics. A total of 10 matched pairs of subjects took part in this phase of the study which focused 
on cytokines. They were randomised to treatment sequences (A and B) using random number tables. 
The actual exercise intervention was a 90-minute -6% downhill run on a treadmill at 75% of VO2 peak 
which was completed 5 days after the subjects started taking either Treatment A or Treatment B. Blood 
samples were obtained from each subject before (PRE), immediately after (IPE), 24 hours (24PE), 48 
hours (48PE) and 72 hours (72PE) after each 90-minute downhill run. 
Treatment interventions were coded by Heel (Pty) Ltd. in Baden-Baden, Germany prior to being 
dispatched to South Africa. Neither the subjects nor the researchers were aware of which treatment was 
active and which treatment was placebo. The coding was only revealed to the researchers once the study 
was complete and a preliminary report of the results was made available to Heel (Pty) 
Subjects continue with 





•Ih Days 7-9 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 
*T f * 1* 
h 
B l o o d s a m p l e s taken 
Field Testing 
1600m run 
1 ¥'fu trial blood samples drawn 
2 Irial-90 minute downhi l l run 
Figure 3.1. Study protocol depicting the time-points. 
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3.3.1. Baseline Laboratory Testing 
At the first test, each subject underwent a pre-study evaluation in order to obtain baseline measurements. 
These included details of exercise training status and anthropometric measures such as height, weight, 
lung-function, resting blood pressure, resting heart rate and percentage body fat. The latter was evaluated 
by the sum of the biceps, triceps, suprailliac and subscapular skin folds according to the technique 
published by Dumin and Womersly (1974). Lung-function was tested using a flow rate spirometer (Jaeger, 
Wuerzburg, Germany). Each subject was required to obtain indemnity from a physician confirming that 
they were free from clinical symptoms of upper respiratory tract infections or other diseases. 
Before the V02max of each subject was determined, they were familiarized with the treadmill to be used 
in the study (A Powerjog GX10, Sport Engineering Limited, Birmingham, England). The subject was then 
allowed to warm up for 5 minutes on the treadmill at a speed of 12 km/hr. After the warm-up period, the 
speed was increased incrementally by 1 km/hr at each minute until fatigue. Fatigue was defined either as 
the subject reporting a Rate of Perceived Exertion (RPE) of between 8-10, an estimated maximal age-
predicted heart rate or a Respiratory Quotient (RQ) of more than 1.15. The highest V02 over a 30 second 
period was defined as the V02 peak-
During the treadmill tests, respiratory and metabolic responses were assessed using a MetaMax 3B 
Portable CPX metabolic testing system (Cortex Biophysik, GmbH, Leipzig, Germany). Prior to the 
assessments, the gas analyzers were calibrated using ambient air and a gas cylinder containing 5.1% C02 
and 16.7 % 0 2 in nitrogen (Air Products, Durban). A two-litre calibration syringe (Erich Jaeger, GmbH, 
Hoechberg, Germany) was used to calibrate the flow volume sensors. Expiratory flow volume was 
measured using a triple V transducer containing a 660nm optical tubine sensor which was connected to a 
tightly fitting facemask. Oxygen and C02 content of the expired air was measured by oxygen and carbon 
dioxide analysers, using an electro-chemical cell and infrared system, respectively. Expired gases were 
analyzed on a breath- by- breath basis by Metasoft ® software and the rolling 30 s average was used in 
order to record V02 throughout the incremental exercise test. 
3.3.2. Track testing 
Each subject was required to undergo an athletic track test which was conducted at the University of 
KwaZulu-Natal's sports grounds at the Westville campus. This field test was supervised by a national 
athletics coach and consultant (Norrie Williamson). After a short warm up session, each subject was timed 
over approximately 4 laps (1609m) on the athletics track. In addition, the subject's running style 
(footstrike pattern, shoe-wear patterns, inner soles and general gait analysis) was assessed while running 
on the track and downhill (gradient > 5%) The subjects past and current training practices were also 
analysed. Each subject received feedback from the coach including advice of pre-intervention training and 
eating procedures. 
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3.3.3. Matching of subjects 
Subjects were then matched according to baseline measurements taken at the first laboratory visit, their 
anthropometric parameters (mass, height, body-mass indices, percentage body fat), running style, training 
status and performance time in the 1609m field test. This included: 
(i) Gender 
(ii) BMI 
(iii) Current training profile 
(iv) Training age 
as well as at least two of the following: 
Foot strike 
VO2 max 
1609m running time and/or best performance over longer endurance running 
events (5km, 10km, half marathon or marathon), within six months prior to the 
study trials. 
3.3.4. The Intervention and Trial Procedure 
Five days prior to the trial each subject was required to orally take 3 Traumeel or Placebo tablets per day 
(Treatment A or Treatment B) which was provided to them. The subjects were requested to dissolve the 
tablet under the tongue at least 30 minutes before mealtime (or on an empty stomach). On the day before 
the trial the subjects were instructed to avoid any heavy physical exercise. For the morning of the trial, the 
subjects were instructed to eat the following breakfast, three hours beforehand: 30g cornflakes, 150ml of 
low fat milk and 12-15 g refined sugar. 
Each subject was then required to report to the exercise laboratory in the morning. Particular care was 
taken to ensure that trials took place at the same time of day to avoid possible confounding of the 
circulating Cortisol concentrations. Following a half hour rest period, pre-exercise venous blood samples 
were obtained from the antecubital vein of each subject. The subjects were allowed to do basic stretching 
exercises immediately prior to the trial. 
Thereafter, each subject underwent a downhill run on a motorised treadmill set at a -6% downhill gradient. 
Their running speed was set at a workload at which they achieved 75% of the individual maximal oxygen 
consumption (75% VO2 peak). During each trial, the subjects' heart rate was continually monitored. The 
oxygen consumption was monitored at 20min intervals using a Metamax metabolic analyser (Cortex 
Biophysik, GMBH, Leipzig, Germany). At 30 minute intervals, the workload was reduced to 50% V02 
peak in order to allow subjects to rehydrate. Each subject was given 500ml of water over the 90-minute 
period. 
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3.3.5. Post-Trial Recovery 
On completion of the exercise trial a 30ml blood sample was drawn from an antecubital vein immediately 
after the trial and at 24hrs, 48hrs and 72hrs following the trial. Subjects were requested to return to the 
exercise laboratory at the same time of the morning on post-trial days to attain further blood samples and 
to record subjective ratings of delayed onset muscle soreness. All post-trial blood samples were obtained at 
the same time of day to avoid the influence of diurnal rhythms on Cortisol concentrations. The participants 
were asked to refrain from any strenuous exercise and to avoid the intake of anti-inflammatory medication 
/painkillers for 3 days after the trial. 
3.4 Treatment of the blood samples 
Aliquots of 3ml of fresh venous blood were drawn into K3 -ethylene diaminetetra-acetic acid (EDTA ) 
tubes for the testing of a full blood count (FBC).Five millilitres of the remainder were allowed to clot at 
ambient temperature, the serum separated and 0.5ml aliquots thereof stored at -70° C for later analysis of 
creatine kinase and Cortisol. The remaining blood was drawn into vacutainer tubes containing EDTA and 
the plasma separated. This was stored at -70° C for later measurement. 
3.5. Analysis of Blood Samples 
3.5.1. Determination of Serum CK and Cortisol Concentrations 
Blood samples and serum was sent to a local Chemical Pathology Laboratory (Global Clinical and Viral 
Laboratories, Jacobs, Durban). Full blood counts including differential leukocyte counts were performed 
on EDTA treated specimens using standard haematological procedures on an automated STKS model 
(Coulter Electronics Inc., Hialeah, Florida, USA). Serum was analysed for CK concentration using a 
Synchron CX, X5Analyser (Beckman Coulter, SA (Pty) Ltd., Halfway House, South Africa). 
Serum Cortisol was assayed using the Gamma Coat radioimmunoassay procedure (AB Advia Centaur 
CPAdviacentaur, Siemens Medical Solutions Diagnostics, Deerfield, USA). 
3.5.2. Determination of Plasma IL-6 concentration by sandwich ELISA 
Plasma IL-6 concentration was determined by sandwich ELISA using a commercial kit (eBioScience, San 
Diego, CA, USA). 
3.5.3. Flow Cytometric Analysis of Cytokine Concentrations 
3.5.3.1. Introduction 
The BD™ CBa Human Inflammation Kit (Becton, Dickinson and Company) was used to quantitatively 
measure Interleukin-8 (IL-8), Interleukin-6 (EL-6), Interleukin-10 (IL-10), Tumor Necrosis Factor (TNF), 
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and Interleukin-12p70 (IL-12p70) protein levels in a single sample. This was done using a flow cytometer 
equipped with a 48nm laser capable of detecting and distinguishing fluorescence emissions at 576 and 
670nm (eg. the BD FACScan™ or BD FACSCalibur™ instruments) and BD Cellquest™ Software. 
3.5.3.2. Principle of the test 
Six bead populations with distinct fluorescence intensities were coated with capture antibodies specific for 
IL-8, IL-6, IL-8, IL10, TNF and ILl-12p70 proteins. The six bead populations are mixed together to form 
the BD™ CBA which is resolved in the FL3 channel of a flow cytometer such as the BD FACScan™ or 
BD FACSCalibur™ flow cytometer. 
The capture beads, PE-conjugated detection antibodies, and recombinant standards or test samples were 
incubated together to form sandwich complexes. Following acquisition of sample data using the flow 
cytometer, the sample results were generated in graphical and tabular format using the BD1M CBA 
Analysis Software. The kit provided sufficient reagents for the quantitative analysis of 50 test samples and 
the generation of two standard curve sets. 
3.5.3.3. Preparation of Human Inflammation Standards 
The Human Inflammation Standards were lyophilised and were reconstituted and serially diluted before 
they were mixed with the capture beads and the PE detection reagent. 
This was carried out as follows: 
1. One vial of lyophilised Human Inflammation Standards was reconstituted with 0.2ml of assay diluent 
in order to prepare a lOx bulk standard. The reconstituted standard was allowed to equilibrate for 15 
minutes before the dilutions were made. The vials were agitated vigorously in order to allow mixing, 
but not vortexed. 
2. Twelve 75mm tubes (BD Flacon™, Cat. No. 352008) were labelled and arranged in the following 
order: Top standard, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128 and 1:256. 
3. 900)0.1 of assay diluent was added to the Top Standard tube. 
4. 300 ul of assay diluent was added to each of the remaining tubes. 
5. lOOul of lOx bulk standard was transferred to the Top Standard tube and was mixed thoroughly 
6. A serial dilution was performed by transferring 300|ll from the Top Standard to the 1:2 dilution tube 
and was mixed thoroughly. Several such serial dilutions were conducted by transferring 300ul from 
the 1:2 tube to the 1:4 tube and so on up to the 1:256 tube. All were mixed thoroughly (see figure 3.2 
below). The assay diluent serves as the negative control. 
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300 Ml 100 Ml 300 III 300 MI 300 III 300 Ml 300 III 300 ul 
r\r\r\r\nr\r*r\ 
1:2 1:4 1:8 1:1f 1:12 1*4 1:12« 1:256 
Top Dilution Dilution Dilution Dilution Dilution Dilution Dilution Dilution 
Standard Tub* Tub* Tub* Tub* Tub* Tub* Tub* Tub* 
Figure 3.2. Preparation of Human Inflammation Standard Dilutions 
The appropriate concentration (pg/ml) of recombinant protein in each dilution tube is displayed in Table 
3.1. 
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3.5.3.4. Plasma Assay Procedure 
1. lOul/test of each Human Inflammation Capture Bead suspension was mixed and vortexed briefly. 
2. Mixed beads were pelletted by centrifugation and the supernatant was aspirated. 
3. The bead pellets were re-suspended in Serum Enhancement Buffer (equal in volume to the amount 
removed in step 2) and was vortexed briefly. 
• 30 minute incubation at room temperature was allowed (protected from light). 
4. 50[il of mixed beads were transferred to the assay tube. 
5. The Human Inflammation Standard was reconstituted in the Assay Diluent (15 min). 
6. The Standards were diluted by serial dilutions using the Assay Diluent. 
7. The Standard Dilutions and test samples were added to the appropriate sample tubes (50|il/tube). 
• 1.5 hour incubation at room temperature was allowed (protected from light). 
8. The samples were washed with 1 ml Wash buffer and centrifuged (100 fxl residual volume was left 
after aspiration). 
9. PE Detection Reagent was added (50 [xl/test). 
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• 1.5 hour incubation at room temperature was allowed (protected from light). 
10. The samples were washed with 1 ml Wash buffer and centrifuged. 
11. 300^1 of Wash Buffer was added to each assay tube and the samples were analysed. 
3.5.3.5. Cytometer Setup Bead Procedure 
1. The Cytometer setup beads (vortexed before adding) were added to setup tubes A, B, and C 
(50ul/tube). 
• 30 min. incubation period at room temperature was allowed (protected from light). 
2. 50|Lil of FITC Positive Control was added to tube B and 50u1 of PE Positive Control was added to tube 
C. 
3. 400[il of Wash Buffer was added to tubes B and C. 
4. 450(̂ 1 of Wash Buffer was added to tube A. 
5. Tubes A, B, and C were then used for the cytometer setup. 
3.6. Subjective Rating of Perceived Muscle Soreness 
Subjective ratings of muscular soreness were determined at the beginning of each day following the trial 
with a numerical 0-10 scale where 0 = no pain at all, 5 = moderate, 10 = severe/maximal pain. The 
quadriceps, hamstrings and calf muscles were assessed under four categories: General pain (subject seated 
and relaxed), daily living (walking /moving), Pressure pain (palpation of the muscle area) and Stretch pain 
(stretching the muscle) using the tabulation shown below. 
DAY 
after the trial 
D a y l : 
immediately 





General post-trial pain seated and relaxed 
Quadriceps Hamstrings Calf 
Post-trial pain during daily living while 
walking 
Quadriceps Hamstrings Calf 
0 = no pain at all; 5 = moderate 10 =severe/maximal 
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3.7. Statistical Analyses 
Data were analysed in SPSS version 15.0 (SPSS Inc., Chicago, Illinois, USA). A p-value < 0.05 was 
considered as statistically significant and data are expressed as mean ± SEM. Baseline and field trial 
outcomes were compared between the two groups using paired f-tests. Repeated measures analysis of 
variance (ANOVA) testing was used to compare quantitative normally distributed outcomes over time 
between the experimental (TRAU) and placebo-control (PLAC) groups. Wilks' Lambda was used as test 
statistic with a Simple Contrasts post hoc correction to determine the time-point of the significant 
differences between treatments. Variables that were not normally distributed were log transformed. 
Significant time-group interactions indicated significant treatment effects. Profile plots were generated to 
examine trends. There was very little missing data, but for some outcomes, the final time point result was 
missing in a few (up to four) cases. In this case, repeated measures ANOVA was conducted on four time 
points as well as five and the results were compared. If there was no difference in the conclusion then the 
five time-point comparison was reported. For the DOMS analysis, the average of the three muscle types 
and modes were computed for each day. Repeated measures ANOVA was performed on these averaged 




4.1. Subject Characteristics 
Twenty subjects (12 men, 8 women), aged between 20 and 50 years fully complied with all inclusion 
criteria set for the study. The subject characteristics are provided in Table 5. Paired student Mests indicate 
that the mean ± SEM of the two groups were not significantly different (p < 0.05) in terms of age, stature, 
mass, percentage body fat, body mass index, FVC, FEVi, heart rate and blood pressure at rest (Table 4.1). 
Table 4.1: Physical characteristics of the participants in the PLAC and TRAU groups. Data 
presented as mean ± SEM _____________™____ 




% Body Fat 
Body Mass Index (kg.m"2) 
FVC (L) 
FEVI (L) 
HR Rest (b.min!) 
Systolic Blood Pressure (mm 















68.53 ± 2.49 
15.86 ±0.86 
23.24 ± 0.50 
4.65 ± 0.20 














FVC = Forced Vital Capacity; L/min; FEVJ = Forced Expiratory Volume in 1 second; HR Rest = Resting Heart Rate 
Physiological response to the incremental maximal exercise test is presented in Table 4.2 
Table 4.2: Physiological Reponses to the Maximal Incremental Exercise Test in the PLAC and 
TRAU groups. Data presented as mean ± SEM ___ 
\ <M i y t b l r 
HR max (b.min") 
RPEmax 
VEmax (L. min'1) 
V0 2 Peak (ml.kg.min
1) 
RERMax 
PI \ C ( H - | 0 > 
180.27 ±3.41 
















*Paired t tests, TRAU VS. PLAC; RER = Respiratory Exchange Ratio maximum; V0 2 peak = relative peak oxygen 
consumption; HR max = Maximal Heart Rate 
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The TRAU and PLAC groups did not differ significantly in terms of mean HR max, RPE max, VE max or 
V02 peak (p > 0.05). 
4.1.2 Training Status and Performance during Field Testing 
The mean ± SEM of data relating to the training status and performance in competitive field events of the 
two groups is given in Table 4.3. These indicate that the gender-matched pairs were also well matched in 
terms of average weekly running distance, number of running years, 1609 run time, performance in 5km, 
10 km, half marathon and/or marathon times. Where possible, subjects who were training partners and 
hence trained in similar conditions were matched. 
Table 4.3: Training status of the subjects in the TRAU group and the PLAC group. Data presented 
as mean ± SEM „___™__________™_____^^ 
Parameter TRA1 (n -. 10* PI \( <>/- im /^a lue 
Average weekly rumimg o^stence (km)* 39.00 ± 6.70 38^00 ±4.02 0.160"~ 
Number of running years* 10.30 ±0.17 11.10 ± 1.27 0.700 
1609m time (min)* 5.88 ±0.04 6.16 ±0.24 0.160 
5km time (min)** 18.67 ±0.06 19.50 ±0.19 0.300 
10km time (min)*** 42.75 ±0.51 38.50 ±0.47 0.200 
Half marathon time (min)*** 101.83 ±2.42 102.38 ±4.19 0.650 
Marathon time (min)**** 233.00 ±6.60 228.50 ±5.15 0.670 
*n = 8; **n = 6; ***n = 5; ****n = 3 
A series of graphs depicting the matching of the subject pairs with respect to their training status and 
running performance is presented in Figure 4.1. 
Subject Pair 1 
Average weekly No of running years1609m Time (mins)Half marathon time 
running distance (mins) 
(kms) 
Subject Pair 2 
Average Weekly No of running 1609m Time Halt marathon 
running distance years (mins) time (mins 
(kms) ) 
Subject Pair 3 
Averaae weekly N o °* r u n n i n 9 years') 609m Time (mins) Halt marathon time 
running distance (mins) 
(kms) 
Subject Pair 4 
Average weekly No of running years'! 609m Time (mins) Half marathon time 
running distance (mins) 
(kms) 
Subject Pair 5 Subject Pair 6 
Average weekly No of running years1609m Time (mins) Half marathon time 
running distance (mins) 
(kms) 
Subject Pair 7 
Average weekly No of running years1609m Time (mins) 
running distance 
(kms) 










Average weekly No of running years1609m Time (mins)Half marathon time Average weekly No of running years1609m Time (mins)Half marathon time 
running distance (mins) | running distance (mins) 
(kms) (kms) 
Subject Pair 9 Subject Pair 10 
Average weekly running No of running years 1609m Time (mins) ' Average weekly running No of running years 1609m Time (mins) 
distance (kms) distance (kms) 
Figure 4.1. The matching of the subject pairs with respect to their training status and performance. 
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The mean ± SEM performance values during the 90-minute downhill trial are given in Table 4.4. While 
average speed and distance covered was slightly greater (p < 0.05) in the TRAU group during the 90-
minute downhill running trial, relative degree of exertion as reflected by the mean RPE, heart rate and 
maximum heart rate and RPE was not significantly different (p > 0.05). 
Table 4.4: Performance of the subjects TRAU and PLAC groups in the 90-minute downhill running 
trial. Data presented as mean ± SEM ________________________^^ 
Parameter 
Average Speed (Km/hr) 
Distance (km) 
Mean RPE 
Mean Heart Rate 
Maximum Heart Rate 
% of Heart Rate Maximum 
Maximum RPE 
T i n U n / ~ KM 
13.29 + 0.21 
20.13 + 0.29 
4.82 ± 0.26 
159.5 ±1.87 
175.5 ±3.11 
83.9 + 1.32 
6.91 +0.38 




160.7 ± 2.09 
180.3 ±3.41 
85.4 ± 0.66 
7.27 ± 0.35 








*Paired t -tests TRAU vs. PLAC 
4.2 Serum Creatine Kinase 
The mean ± SEM serum CK concentrations in the TRAU and PLAC groups is depicted in Figure 4.2. The 
CK concentration rose significantly in response to 90-minutes of downhill running in both groups (p < 
0.001), peaking at 24 hours post exercise and remained significantly elevated in the 48 PE and 72 PE 
serum samples (p < 0.05) despite relatively large variances within the groups. The time effect between the 
TRAU and PLAC groups was highly significant (p < 0.001), but the treatment-time interaction did not 
reach statistical significance (p - 0.398; repeated measures ANOVA, Wilks' Lambda test statistic). 
Simple contrasts post-hoc analyses revealed that the absolute CK concentration differences were only 
statistically significant at the IPE time point {p = 0.04). 
2500 
Pre Post 24 Post 48 Post 72 Post 
Figure 4.2: Mean ± SEM serum creatine kinase concentrations of the TRAU (n = 10) and PLAC (n = 10) groups 
before and after 90-minutes of downhill running on a treadmill, # p < 0.05 Time-effect, repeated measures ANOVA, 
Wilks Lambda Test Statistic ** p < 0.05 Simple contrast post hoc comparison between groups at time point 















Pre Post 24 Post 48 Post 72 Post 
Figure 4.3 : Mean ± SEM neutrophil concentrations in the TR AU (n = 10) and PLAC groups (n = 10) before and 
after the 90-minute treadmill trial. # p < 0.05 Time-effect, repeated measures ANOVA, Wilks Lambda Test Statistic, 
*p < 0.05 Simple contrast post hoc comparison vs PRE 
Figure 4.3 reflects that the absolute neutrophil counts (109.L~') were significantly increased at the IPE time 
point (p < 0.001) and returned to near pre-trial values within 24 hours in both the TRAU and PLAC 
groups. The time effect between the TRAU and PLAC groups was highly significant (p < 0.003), but the 
treatment-time interaction did not reach statistical significance (p = 0.940; repeated measures ANOVA, 





Post 24 Post 48 Post 72 Post 
Figure 4.4: Mean ± SEM serum Cortisol concentrations of the TRAU (n = 10) and PLAC (n = 10) groups before and 
after 90-minutes of downhill running on a treadmill *p < 0.05 Paired Mests vs PRE; ** p < 0.05 Simple contrast post 
hoc comparison between groups at time point 
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Figure 4.4 graphically displays changes in serum Cortisol concentrations for the the TRAU and PLAC 
groups. The TRAU group increased to a peak of 754.2 ± 340.5 nmol/£ while the control group reached a 
peak of 600.6 ± 148.4 nmol/£ (p < 0.001). In both groups, the decline in serum Cortisol concentrations 
was significant at 24 hours (p < 0.001) and by 72 hours, both groups had returned to near-pre trial Cortisol 
levels. 
Repeated measures ANOVA revealed that the time effect was highly significant (p < 0.001) in both 
treatment groups, but the group-time interaction did not reach statistical significance (p = 0. 767). Simple 
contrast post hoc analyses verified these findings (p > 0.05) at each of the time points. 
4.5. DOMS 
Day1 Day 2 Day 3 Day 4 
Time 
Figure 4.5: Mean ± SEM reported peak DOMS scores of the TRAU (n — 10) and PLAC (n = 10) groups following 
participation in a 90-minute downhill run ; ** p < 0.05 Simple contrast post hoc comparison between groups at time 
point 
The mean ± SEM post-trial DOMS scores reported by the TRAU group over the 3-day post-exercise 
recovery period, were significantly different from those reported by the PLAC group (p = 0.04). Figure 4.5 
depicts that the mean DOMS score peaked at Day 2 post trial and declined steadily thereafter. The 
majority of subjects reported that pain was elicited during activities and walking as opposed to at rest. The 
muscle groups most affected were the quadriceps muscles, followed by the calf muscles. The hamstring 
muscle group was the least affected. Five subjects reported pain in all muscle groups. The overall means 
of the DOMS scores over the four days following the trial were analysed using repeated measures 
ANOVA tests not did not reveal a significant group-time interaction over the three days post exercise (p = 
0.68). The difference between the two groups was significant 24 hours post-trial (p < 0.03; Figure 4.5). 
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4.6. Plasma TNFa concentrations 
The mean ± SEM of TNFa immediately before, after and 24 hours after the 90-minute trial run are 
presented in Figure 4.6. The 90-minute run did not result in a significant change in TNFa (p > 0.05) when 
compared to the pre-test values. The values remained within the normal range throughout the 24 hour 












Pre Post 24 Post 
Figure 4.6: Mean ± SEM plasma TNFa concentrations (pg/ml) of subjects in the TRAU (n = 10) and PLAC (n = 10) 
before and after participation in the 90-minute trial at 3 time-points 
4.7. Plasma IL-6 concentrations 
The mean ± SEM of IL-6 concentrations determined by ELISA immediately before, after, 24, 48 and 72 
hours after the 90-minute downhill trial run, are presented in Figure 4.7. The downhill run resulted in a 
small (5-fold, 5.2 fold), but significant elevation in IL-6 (p < 0.05) when compared to the pre-test values. 
The difference in the exercise-induced change between the two groups was, however, not statistically 
significant {p > 0.05). IL-6 concentrations reached baseline levels within 24 hours following the run and 









PRE IPE 24 PE 48 PE 72 PE 
Figure 4.7: Mean ± SEM plasma IL-6 concentrations (pg/ml) of subjects in the TRAU (n = 10) and PLAC (n = 10) before and 
after participation in the 90-minute trial at 5 time-points, #p< 0.05 Time-effect, repeated measures ANOVA, Wilks Lambda Test 
Statistic, * p < 0.05, Simple contrast post hoc comparison vs. PRE 
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4.8. Plasma IL-8 concentrations: 
24 Post 
Figure 4.8: Mean ± SEM plasma IL-8 concentrations (pg/ml) of subjects in the TRAU (n = 10) and PLAC (n = 10) 
before and after participation in the 90-minute trial at 3 time-points, *p < 0.05, Simple contrast post hoc comparison 
vs. PRE 
The mean ± SEM of IL-8 concentrations immediately before, after and 24 hours after the 90-minute 
downhill trial run, are presented in Figure 4. 8. In the TRAU and PLAC groups, there was a significant 
elevation in IL-8 (p < 0.05) when compared to the pre-test values. The difference in the exercise-induced 
change between the two groups was, however, not statistically significant (p > 0.05). IL-8 concentrations 
reached baseline levels in both groups within 24 hours following the run. 
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Figure 4.9: Mean ± SEM plasma IL-10 concentrations (pg/ml) of subjects in the TRAU (n =10) and PLAC (« = 10) 
before and after participation in the 90-minute trial at 3 time-points, # p < 0.05 Time-effect, repeated measures 
ANOVA, Wilks Lambda Test Statistic, *p < 0.05, Simple contrast post hoc comparison vs. PRE 
Figure 4.9 reveals that the mean ± SEM plasma IL-10 concentrations rose significantly in both groups 
following the downhill exercise protocol (p < 0.001; p = 0.03) with mean concentrations peaking at 9.99 
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and 10.11 pg/ml respectively. The time effect was statistically significant throughout the 24 hour period, 
but the time-group interaction (p > 0.05) did not reveal a significant difference between the two groups. 
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Figure 4.10: Mean ± SEM plasma IL-12p70 concentrations (pg/ml) of subjects in the TRAU (n - 10) and PLAC (n 
10) before and after participation in the 90-minute trial at 3 time-points 
The mean ± SEM of IL-12p70 concentrations immediately before, after and 24 hours after the 90-minute 
downhill trial run, are presented in Figure 4.10 and Table 4.5. Due to the large variance in the results, the 
exercise trials were not found to result in a statistically significant increases in the plasma IL-12p70 
(pg/ml) concentrations and no significant group-time effect was observed in these cytokine 
concentrations^ > 0.05). 
Table 4.5: Plasma TNF- a, IL-8, IL-10, IL-12p70 concentration preceding and following the trial 
run. Data presented as mean ± SEM 
Parameter 
TNFa (pg/ml) 
1 R U Croup 
PI \< (.1 OU|) 
IL-8 (pg/ml) 
TRAD (.roup 










11. 62 ±0.69 








23.94 ± 1.63 
17.60 ±7.06 




24 1 Irs Post 
ND 
3.84 ±2.11 















*Time Effect, Repeated Measures ANOVA, Wilks Lambda Test Statistic, ND: Not detected 
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While Table 4.5 presents the results of flow cytometric bead array analyses at only three time points before 
and after the 90-minute trial, Table 4.6 presents the results of the Elisa analysis of IL-6 at each of the 5 
time points in the study. 
Table 4.6: Plasma IL-6 concentration preceding and following the trial run. Data presented as mean 
±SEM 
J ' i i C i i m c t i ' i 
I I - 6 
I K \ I Group 




I V l 
8.89 ± 0.98 
12.31 ±3.23 
?t Mi- I V s 
2.71 ±0.65 
2.52 ± 0.46 
IK Hi-. IV-1 
2.84 ±0.37 
3.40 ± 0.63 
~2 Hi- I V ! 
2.00 ± 0.43 
2.95 ± 0.66 
jt i . i ln t '"' 
0.000 
0.637 




This trial presented with numerous challenges. Although it would have been ideal to use each subject as 
their own control and conducted a classic cross-over, double-blinded-placebo controlled trial, this was not 
possible due to the well-described confounding repeated bout effect (McHugh et a/., 1999, 2003). As 
previously described, the training effect of the first 90-minute downhill running trial would have resulted 
in an attenuation of most markers of the inflammatory response to eccentric exercise (Hortobagyi et ai, 
1997, 1998; McHugh et al., 1999; McHugh, 2003, Lavendera and Nosaka, 2008). This would have 
significantly impacted the results of the second trial run even after the wash-out period and has been 
shown to persist for up to 3 months post-exercise (Hortobagyi et ai, 1997, 1998; McHugh, 2003) 
Therefore matched pairs were selected to participate in the study and every attempt was made to ensure 
optimal matching. It was felt that this study design was superior to randomizing subjects when the sample 
size was so small. 
As is evident in Tables 4.1, 4.2 and Figure 4.1, subjects in the two groups were not significantly different 
(p > 0.05) in terms of age, stature, mass, percentage body fat, body mass index, FVC, FEV], RER Max, 
V02 Peak, VEmax, and heart rate at rest. They were also well matched with respect to their average weekly 
running distance, number of running years, 1609 run time, performance in 5km, 10km, half marathon 
and/or marathon times. Where possible, subjects who were training partners and hence trained in similar 
conditions, were matched. 
5.1. Pre-Trial Data 
Although every attempt was made to match the subjects in terms of the factors mentioned above, it would 
appear that the subjects in the TRAU group entered the trial slightly less well-rested than those in the 
PLAC group. This is reflected by the differences in the mean creatine kinase concentrations between the 
two groups in the pre-trial samples (p < 0.05). We also confirmed the findings of Jordaan, (2006) of a 
higher pre-trial Cortisol concentration in the TRAU group following the 5 days of Traumeel administration. 
As the anti-inflammatory effect of Cortisol is well recognized, this may be a beneficial effect of Traumeel 
and does require further verification in studies with larger sample sizes. 
5.2. Trial Performance 
Subjects in TRAU group ran slightly faster and covered a slightly greater distance during the 90-minute 
run than subjects in PLAC group (p < 0.05). This difference was statistically significantly (p = 0.03; p = 
0.02). However, with respect to the relative degree of exertion as reflected by the mean RPE, heart rate and 
maximum heart rate and RPE, there were no significant differences between the TRAU and the PLAC 
096845 
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groups during the 90-minute downhill trial run (p > 0.05). Although this may have indicated a slightly 
superior training status in the TRAU group, analyses of the training and race profile (Table 4.3 and Fig 
4.1.) indicates no difference between the groups. 
The possibility of a lesser relative perception of effort and chronotropic adaptation to the higher work rate 
following 5 days of TRAUMEEL administration in the TRAU group requires further investigation. 
Although this has not been previously shown in scientific studies, numerous anecdotal reports do exist. It 
is important that the post-trial recovery rates are evaluated in relation to the increased amount of work 
done and greater power output in the TRAU group during the 90-minute trial. 
5.3. Post-Trial Data 
The effect of the 90-minute downhill running trial was as follows: 
o A significant increase in leucocytes/neutrophil count in both treatment groups. 
o A significant increase in blood Cortisol concentration in both treatment groups. 
o A significant increase in creatine kinase concentration in both treatment groups. 
o No change in the concentrations of plasma: 
• TNF-a 
• IL-12p70 




in both TRAU and PLAC groups. 
Despite the relatively small downhill gradient (-6%), these confirm the findings of Ostrowski et al., 1998b, 
1999; Singh et al, 1999; Nieman et al, 2000; Peters et al, 2001b; Starkie et al, 2001; McKune, 2006; 
Smith et al, 2007 with respect to Cortisol, creatine kinase and IL-6, IL-8, IL-10 cytokine concentrations. 
5.4. Serum Creatine Kinase 
Our findings following the 90-minute bout of downhill running support those of McKune et al. (2006) 
who found that a 60 minute bout of downhill running at a gradient of -13% resulted in substantial elevation 
of CK post-exercise. Interestingly our CK concentrations peaked at 24PE (1394.8 ± 273.96 in the TRAU 
Group and 915.9 ± 192.46 in the PLAC group). 
Of greatest interest is the fact that the faster running speed and greater distance covered on the treadmill by 
the runners in the TRAU group, elicited a greater evidence of muscle damage in the TRAU group (n = 10) 
in the IPE samples (p < 0.05), but not in the 24PE, 48PE, and 72PE samples. This would appear to reflect a 
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more rapid recovery in the TRAU group. The faster mean recovery rate was, however, not of statistical 
significance (p > 0.05). this was most likely due to large intra-group variance. 
5.5. Neutrophil Counts 
These results confirm that the downhill running protocol of 90-minutes, at a gradient of -6% and running 
speed which elicited 75% of V02 peak, was sufficient to result in a significant elevation (p < 0.03) in 
neutrophil counts in both TRAU and PLAC groups. 
They confirm the previously described exercise-induced neutrophilia which has been reported to be related 
to increasing serum Cortisol concentrations (Pedersen, 1997) and to also be indicative of an acute reaction 
to the microscopic muscle damage inflicted by the downhill running protocol. 
The findings of this study revealed that despite the faster running speed, no significant time-treatment 
interaction was shown between the TRS and PLAC groups in terms of WBC and neutrophil response to 
the exercise protocol over the three-day period. This appears to indicate that TRAU does not act by 
inducing the mobilisation of neutrophils in response to microscopic muscle damage. 
5.6. Serum Cortisol 
As particular care was taken to ensure that post trial blood sampling occurred at the same time of day, the 
diurnal rhythm of Cortisol release from the adrenal gland was accounted for. The pre-exercise mean of 
419.8 ± 209.8 and 320.3 ± 88.7 (which falls into the upper bracket of the morning reference range of 
Cortisol) in the TRAU and PLAC groups is attributed to the fact that all trials took place in the morning, 
most starting before 9am. 
The significantly higher pre-trial concentrations in the TRAU group following 5 days of supplementation, 
confirm the findings of Jordaan (2006) who also reported elevated pre-trial Cortisol concentrations in the 
TRAU group. As large variations in baseline Cortisol concentrations do exist between individuals (Peters, 
2001 b), the finding, however, requires validation in a larger study before possible mechanisms of action 
are investigated. 
The concentration of Cortisol rose significantly following the 90-minute run in both the TRAU and PLAC, 
but had returned closer to baseline levels 24 hours post the trial-run with a significant (p = 0.001) time-
effect in both groups. As is reflected by the close to parallel alignment of the line graphs of the two groups, 
the group-time effect was, however, not statistically significant (p = 0.767). 
The almost two-fold (200%) rise in serum Cortisol concentrations exceeds the 50% rise reported by 
McKune et al. (personal correspondence, 2006) following 60 minutes of running at a steeper gradient of -
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13.5%. The rise would most likely have been caused by the damaging effect of downhill running on 
muscle fibers in both the TRAU and PLAC groups over the 90 minute period. It is well described in the 
literature that the debris produced by the muscle tissue damage activates the macrophages that are resident 
in the muscle tissue, which produce pro-inflammatory cytokines, including TNF-a and IL-lp\ which, 
amongst other functions, increase cell membrane permeability and the influx of lymphocytes, neutrophils, 
monocytes to the damaged tissue and activate the release of Cortisol from the adrenal cortex (Malm et al, 
1999; Pederson and Toft, 2000). The resultant release of anti-inflammatory cytokines into the circulation 
(Figure 2) is important in restraining the inflammatory response and accelerating the healing process ((Van 
Brandt, 2002). 
Interestingly, despite the consistently higher mean Cortisol concentrations in the TRAU group over the 5 
time points, the difference between the two groups was not statistically significant. As the range of serum 
Cortisol concentration is great between individuals, the large variance in combination with the low power 
of the study, is the most likely reason for this. A larger study involving greater sample sizes is thus 
imperative to clarify this potentially important anti-inflammatory mechanism by which Traumeel may act. 
5.7. Plasma TNF - a 
The 90-minute run did not result in a significant change in TNF-a concentrations when compared to the 
pre-test values (p = 0.243, p = 0.165). TNF-a concentrations were, however, undetected in numerous 
samples and the values remained within the normal range throughout the 24 hour period pre and post trial 
(Nieman, et al, 2001, although Hirose et al, 2004). No time effect (p = 0.167) and no group time-
interaction (p = 0.547) was noted. 
Numerous reports (Ostrowski et al., 1998; Croisier et al, 1999; Ostrowski et al., 1999; Nieman et al. 2000; 
Toft et al, 2000; Starkie et al, 2001; Hirose et al, 2004; Smith et al, 2007), especially those following 
eccentric exercise, indicate that there is no significant exercise-induced increase. Firstly, the half-life of 
circulating TNF-a is short (14-18 minutes) and the kidney is a major organ for TNF clearance. A rapid 
renal clearance from the circulation into the urine has therefore been suggested as one of the reasons for 
the failure of TNF-a concentrations to be elevated post exercise (Seckinger et al, 1989 Shek and 
Shephard, 1998; Suzuki et al, 2002). Exercise has also been shown to stimulate the release of soluble 
TNF-a. receptors which inactivate systemic TNF-a release (Ostrowski et al, 1999). Thirdly, prolonged 
exercise results in the release of IL-10 which inhibits NF-KB translocation, promoting degradation of 
mRNA for TNF-a (Opal et al, 1998) and also attenuates surface membrane expression of TNF-a receptors 
and promotes shedding of the receptors into the circulation (Dickensheets et al, 1997; Joyce et al, 1994). 
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The failure of plasma TNF-a concentration to rise and the inability to detect a difference between the two 
treatment groups is thus an expected finding in in vivo work of this nature which involves the response to 
prolonged exercise. 
5.8. Plasma Interleukin - 6 
The mean ± SEM of plasma IL-6 concentrations immediately before, after and 24 hours after the 90-
minute trial run are presented in Table 4.6. The downhill run resulted in a relatively small (±5.2 fold), but 
significant elevation in IL-6 (p < 0.05) when compared to the pre-test values. The difference in the 
exercise-induced change between the two groups was, however, not statistically significant {p > 0.05). 
There appeared to be a significant time effect (Table 4.6, (p < 0.001). The concentrations of EL-6 reached 
baseline levels within 24 hours following the run and did not fluctuate during the subsequent 48 hour 
period monitored. 
Circulating IL-6 concentrations have been shown to increase both during and following bouts of severe 
exercise, especially when muscle mass recruitment is large and exercise is of an eccentric nature. Many 
studies have demonstrated increased levels of DL-6 following bouts of prolonged exercise which results in 
the recruitment of large muscle mass which has been attributed to increased metabolic activity in muscle 
((Ostrowski et al, 1998b, 1999, Singh et al, 1999, Nieman et al, 2001, Starkie et al, 2001 and Peters et 
al, 2001a; 2001b; Smith era/., 2007). 
The exercise-induced increase in IL-6 was, however, relatively modest when compared to previous reports 
in the literature. Several factors could account for this. 
Firstly, relatively low metabolic activity during downhill running when compared to running uphill or on a 
level surface, would explain relatively small exercise-induced increases in IL-6 measured immediately 
post exercise. In this regard our findings confirm those of Ostrowski et al.{ 1998b); Nieman et a/.(2001); 
Smith era/.(2007). 
In terms of an inflammation responsive reaction occurring after completion of the eccentric exercise, the 
timing of the post-exercise sample may have been an important factor. Previous research (Ostrowski et 
al., 1998b) has shown that when the increase in IL-6 is the result of muscle damage, it only peaks in the 
blood stream after 30-minutes. As our samples were taken immediately post-exercise, this may also 
account for the moderate increase we reported. 
It is, however, interesting that despite the greater distance covered, faster running speed and higher CK 
concentrations in the TRAU group, IL-6 concentrations were not significantly higher in the TRAU group 
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pointing towards the possibility of an attenuated inflammatory response in this group. This requires further 
investigation in a larger study. 
5.9. Plasma Interleukin - 8 
The downhill run resulted in an approximately 9-fold increase in the serum concentrations of IL-8 in the 
TRAU group and the PLAC group. This represented a significant elevation (p < 0.05) in IL-8 serum 
concentration between the pre and post test concentrations. However, the difference in the exercise-
induced change between the two groups was, not statistically significant (p > 0.05). IL-8 concentrations 
reached baseline levels within 24 hours following the run. The Repeated Measures ANOVA test revealed 
that neither the increase in concentrations over time nor the time-group interactions were significantly 
different (p = 0.129, p = 0.327). 
The results of this study concur with the results of other studies which revealed that following periods of 
intense eccentric exercise or periods of exhaustive exercise, serum IL-8 concentrations have been shown to 
be significantly elevated in the blood (Nieman et al., 2000; Suzuki et al., 2000; Nieman et al., 2001; 
Ostrowski et al., 2001; Smith et al., 2007). In both groups, the downhill running protocol therefore not 
only resulted in increased neutrophil concentrations in the blood, but also increased the concentrations of 
the chemotactic cytokine, IL-8. As the concentrations of the two groups were, however, not significantly 
different between the two groups despite the higher workload in the TRAU group, the findings of this 
study do not provide evidence of increased chemotactic stimulus for phagocytes following ingestion of 
Traumeel®S. 
5.10. Plasma Interleukin -10 
The mean ± SEM plasma IL-10 concentrations rose significantly in both groups following the downhill 
exercise protocol (p < 0.001; p = 0.03) with mean concentrations peaking at 9.99 and 10.11 pg/ml 
respectively. The time effect was statistically significant throughout the 24 hour period (p = 0.02), but the 
time-group interaction (p > 0.05) did not reveal a significant difference between the two groups. 
IL-10 is part of the primary anti-inflammatory cytokine group and acts by inhibiting pro-inflammatory 
cytokine production by monocyte and macrophage activation. The findings of this study support those of 
Peters et al. (2001b), Suzuki et al. (2002), Smith et al (2007) who reported that high intensity exercise of 
extended durations may induce the release of IL-10 into the circulation. 
As the downhill protocol used in the study, did according to the raised CK levels and degree of post-
exercise neutrophilia, induce muscle microtrauma, post-exercise elevation of IL-10 was an expected 
finding (Peters et al.., 2001b; Peters, 2004). The rise in IL-10 was, however, not different between the 
TRAU and PLAC trials, despite the significantly greater running distance and faster running speed, a 
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finding which is in alignment with that of the Cortisol, IL-6 and IL-8 results. This supports the possibility 
of a protective effect in the TRAU group. 
5.11. Plasma Interleukin - 12p70 
Due to the large variance in the results, the exercise trials were not found to result in a statistically 
significant increase in serum IL-12p70 (pg/ml) concentrations and no significant group-time effect was 
observed in the cytokine concentrations (p > 0.05). This confirms the findings if Akimoto et al. (2000) and 
Suzuki et al. (2002). 
While the inconsistencies and lack of reproducibility have been attributed to the rapid down-regulation of 
IL-12 levels following exercise and to different measurement methods (Suzuki et al., 2002; Smith et al., 
2007), it is also of interest that the p70 subunit and not the p40 subunit was measured. In view of the 
important function of IL-12 in activating Thl cells, this failure of IL-12p70 to increase significantly, was 
an expected finding. On the one hand , it may be interpreted to indicate that the exercise protocol was not 
intense enough to downregulate the Thl cells and hence cell-mediated immunity. On the other hand, 
measurement of the p40 subunit may have provided more valid data and would have been a more 
advisable choice in view of the recent findings of Suzuki et al. (2003). 
58 
Chapter 6 
Conclusions and Recommendations 
Despite the shortcomings of this study which include a relatively small sample size and limited statistical 
power, several interesting observations were made. 
1. The subjects in the TRAU group presented with higher pre-trial blood CK and Cortisol 
concentrations than the PLAC group after administration of Traumeel® S for 5 days. This requires 
further investigation. 
2. In both TRAU and PLAC groups, the exercise-induced increase in IL-6, 11-8 and IL-10 
concentrations, provided evidence of an inflammatory response to the downhill running protocol 
and an upregulation of the Th2 cells. The failure of IL-12p70 to increase significantly, however, 
appears to indicate that the downhill running protocol was not intensive enough to downregulate 
Thl cells and suppress cellular immunity. 
3. Although the subjects in the TRAU group did not report a superior competitive performance or 
training status profile before the study (p > 0.05), the average running speed and distance covered 
in the 90-minute trial was greater than the subjects in the PLAC group. This was confirmed by 
higher 24hr post-trial CK concentrations. Despite this, their mean and maximum RPE (p = 0.441) 
and mean and maximum heart rate (p = 0.209) was not greater. In addition, blood Cortisol, IL-6, 
IL-8 and IL-10 concentrations were not significantly higher in the TRAU group. In view of the 
higher work output of the TRAU group during the 90-minute trial, this is, however, indicative of a 
possible protective effect of Traumeel®S and is worthy of further investigation. 
A number of directions for future research can also be identified from the findings of this study. These 
include the following: 
1. In future studies, the p40 subunit of IL-12 should be measured in order to verify the conclusion 
that downregulation of Thl cells does not occur following an exercise protocol of this nature and 
that Traumeel does not act on the cellular component of the immune system. 
2. Every attempt also needs to be made to ensure that subject pairs complete the same amount of 
work on the treadmill over the specified time-period in order to ensure that the intervention 
designed to induce muscle damage, is equal for the two groups. While more precise matching of 
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pairs may, however, be difficult, a larger sample size would ensure that significant differences 
would not exist in a randomized, double-blind study of this nature. 
3. Molecular investigations into the expression of NF-KB would be valuable in confirming the 
findings of the inflammation responsive cytokine milieu in a further study, while measurement of 
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Study Title: The effect of an anti-inflammatory homeopathic product on systemic 
markers of inflammation following downhill running. 
Introduction: This study will investigate the effect of Traumeel, an homeopathic anti 
inflammatory product, on the delayed muscle soreness (DOMS) which occurs following 
prolonged exercise. As we arc interested in establishing the mechanisms which result in 
this muscle soreness and whether this can be minimized by the use of homeopathic 
preparations, we shall be doing a variety of analyses on your blood samples before and 
after exercise. 
Who will qualify to participate in this study? Thirty healthy long-distance athletes 
aged 20 -50 years 
non-smokers, non-diabetic, free of cardiovascular impairments (as verified by 
medical practitioner) 
not showing clinical signs of infection (as verified by medical practitioner) 
taking no medication (e.g. analgesics or anti-inflammatories) 
covering a minimum of 30 km per week in training 
What will be expected from volunteers in this study? 
You will be asked to: 
- not use any analgesics, anti-infective or anti-inflammatory or Vitamin C 
preparations in addition to the prescribed study supplements for 2 weeks 
before and for the duration of the trials. 
- maintain your usual diet for the duration of the trials. 
- maintain the same type of training during the trial period 
avoid any heavy physical exercise the day before each exercise trial. 
Outline of tests and trials: 
First Laboratory Visit -Exercise Laboratory, Physiology Department, Nelson 
Mandela Medical School: approx two weeks before trial) 
Interview regarding exercise training status, medical status 
Assessment of height, mass and percentage body fat (to be estimated from 
skinfold thicknesses) 
- Lung function test 
- Resting heart rale and blood pressure measurement 
- VO2 peak, lest on treadmill: After a 5 minute warm-up al a relevant pace, 
expired air will be collected and analysed as running speed will increase bj 
Field visit - University of KZN - Sports grounds Francois Rd Track (approx 
week before trial) 
Warm up at relevant pace - subject will be timed over 4 laps (1609m) on track 
wilh heart rate and time recorded. 
Recording and analysis of past and current training processes 
Analysis of running style and feedback (as above) 
Race schedule analysis for past month and following month (as above) 
Explanation of pre- intervention training and eating procedures. 
Intervention Trial to be conducted in the Exercise Laboratory, Nelson R, 
Mandela School of Medicine. 
The protocol of each of the intervention trial will be the following: 
5 days prior to the trial - 1 x TRAUMFEL tablets 3 X per day (provided) 
sublingually before meals. 
The morning of the trial - the following breakfast is to be eaten 3 hrs before the trial 
:30g cornflakes, 150ml of low fat milk and 12-15 g refined sugar 
The exercise trial - 30ml blood sample to be taken on arrival 
exercise protocol - wearing a heart rate monitor, six subjects to run or 
treadmill in the exercise laboratory for 90 minutes in a relaxed atmosphere 
TV screens/music will be available to entertain the runners on the treadmill 
and free communication between runners and research assistants will be 
encouraged. The running speed will be individualized according to the results 
of the VO2 max tests and the 1609m time trial. 
30ml blood sample will be drawn 1, 24, 48 and 72 hours after the trial 
The order of the trials is to be randomized. By this we mean that you will be placed into 
treatment sequences using random number tables. You may therefore not be receiving the 
treatment in the same order as the other subject(s). As it is to be a double blind study. 
neither the researchers or you will be informed regarding which treatment you arc on. 
The products are to be coded as placebo or active substance in the chemical laboratory 
before distribution to the subjects. 
How can you benefit from participation in this study? 
Following completion of all aspects of the trial, you will receive 
the results of your VO^pok test 
the results of your full blood counts and other biochemical/ laboratory tests which 
were run on your blood samples. 
a prediction of your current ability / potential at various race distances from 5km to 
Comrades marathon (as relevant to your goals / Training) 
a list of training paces relevant to your current ability 
information on your running style and relevance of your current running shoes to this 
style. 
an indication, based on the information supplied, as to the relevance of your current 
training to running goals 
A furthering of the knowledge regarding supplementation procedures which will optimize 
troth your performance and the stiffness you feel following exercise, will be obtained 
from this work. You will be the first to be notified of the results of this study. 
Will you be exposed to adverse effects of the exercise or side effects from Traumeel 
As with all exercise exposure, it is possible that an accident may occur (e.g. that you may 
perhaps fall). In the event of your heart or one of your other organs having a disordei 
which has to date, not been diagnosed, the increased blood flow to the heart and 
increased mean blood pressure during exercise may also result in a heart problem or other 
organ damage occurring while you arc exercising. This is the reason why we have beer 
*o careful in terms of who we have allowed to participate in the study. Do, however, also 
i>e assured that there will be medical personnel present or on call throughout all aspects 
of die testing and that the laboratory is fully equipped with first aid and emergency 
xjuipment. 
In terms of possible side-effects from the Traumeel supplementation thai you will be 
using, although some people do sometimes develop mild headaches, diarrhoea or nausea, 
recent studies have shown that these resolve without discontinuation of the treatment and 
it has not been proven that these are directly related to ingestion of TraumeeL 
As with all prolonged exercise involving downhill running, you should expect a certain 
amount of muscle soreness 48-72 hours post-exercise. This will be carefully monitored 
jsing a 0-10 numerical scale recording your levels of discomfort. It is also worth noting 
that previous studies and coaches suggest that the downhill training session will 
assist in protecting yon from muscle soreness and muscle inflammation during other 
downhi l l sess ions o v e r t h e fo l lowing 3 m o n t h s (Nosnka K, Sakamoto K, Newton M, SBCCO P. HOW lone 
Joes the protective 
*fect on eccentric exercise-Induced muscte damage last? Medici .Sports Exerc., 33: 1490-1495. ) . S h o u l d VOU b e 
participating in a competitive event involving downhill running following 
participation in this trial, you are therefore assured of a beneficial training effect for 
at least 3 months thereafter. 
Can you withdraw from the study? 
As participation is entirety voluntary, you may withdraw from the study at any time 
without penalty. 
Will your individual results remain confidential? 
Yes. The records identifying the participant will be kept confidential and, to the extent 
permitted by the applicable laws and/or regulations, will not be made publicly available, 
[f the results of the study are published, the participant's identity will remain confidential 
Sponsorship of the study/Financial compensation 
rhe Traumeel and placebo products to be used during the study will be manufactured in 
Germany, and packaged and distributed to you by Heel Pty Ltd, South Africa in 
lohannesburg. 
Study Director 
Department of Physiology, 
Faculty of Health Sciences 
University of KwaZulu-Natal 
Athletics Coach and Consultant: 
Further queries? 
Should you have any queries or wish to obtain further details regarding this study, please 
to not hesitate to contact us. 
Professor Edith Peters-Futre - (031) 260-4237(w); 261-3869(h). 
Norrie Williamson - 031-2017687 
www.coachnorric.co.za 
Post-graduate research assistants: 
Dr Aadil Docrat, Department of Physiology 
Ms Megan Smith, Department of Physiology 
Ms Smith and Dr Docrat will be assisting wiUi the implementation of this study and 





Verif ication f rom General Practit ioner 
Dear Dr 
__________________________ is be ing cons idered as a potent ia l 
subject in the fol lowing research project which is to take place on t ra ined 
endurance athletes in our Department in May 2005. 
Title of Project: The effect of an anti- inf lammatory homeopathic product o n 
systemic markers of inf lammation fol lowing downhil l running. 
As a precaut ion we would like y o u to verify that you have examined this patient 
recently and are not aware that he has any cardiovascular or metabol ic problems 
e.g. d iabetes which may result in it be ing hazardous for h im to part ic ipate in the 
study. 
W i th sincerest appreciat ion, 
Dr E M Peters-Futre 
Exercise Physiologist 
Department of Physiology 
Nelson Mandela School of Medicine 
University of KwaZulu Natal 
Private Bag 7, Congella, 
4013, South Africa 
Tel: +27(0)31-2604237 
Fax: +27(0)31-2604455 
I hereby conf i rm that Mr „ has been 
examined by me and I regard h im to be free of cardiovascular impairments which 
may render part ic ipat ion in a 1.5 hr treadmil l run hazardous to his health. 
I also conf i rm that Mr is not a diabetic and 
is medical ly fit to part icipate in this research. 
S igned __ 
Quali f icat ion 
Date 
Day, Date and Time of 
Session 
Rate of perceived 
exertion 
Training Mileage Intensity Sessions 
Type: 
Duration: 
% of max (eg. 50%); 
Type: 
Duration: 
% of max (eg. 50%): 
Type: 
Duration: 
% of max (eg. 50%): 
Type: 
Duration: 
% of max (eg. 50%): 
Rating of Perceived Exertion 
and General Comments 
1= Very easy 2= Easy 3= Moderate 
4= Fairly Exhausting 5=Exhausted 
SUBJECT CONSENT 
FORM 
I hereby agree lo participate in a research study 
to be performed by Edith Peters-Futre and co-workers in the Department of Physiology at 
the University of KwaZulu-Nalal Medical School. 
I understand that the basic procedures involved in this study are to include: 
- Assessments of training history, anthropometric measures, lung function, 
selected baseline clinical measures and an exercise test (VO; peak) during 1* 
Laboratory visit (approx 2 weeks before 90-minule trial in the laboratory). 
- Field test conducted by Norrie Williamson which will consist of a 4 lap 
(1609m) time-trial on the KZN athletics track with heart rate and time 
recorded (1 week before 90-minule trial in the laboratory). 
- Sublingual intake of 1 x TRAUMEEL or placebo tablet 3 x per day 30 
minutes before meals at each meal (i.e. 3 x per day), for 5 days prior to the 
exercise trial (to be held in the Exercise Laboratory, Nelson R Mandela 
School of Medicine. 
• Having a 30ml blood sample taken on arrival at the 90-minute exercise trial. 
- Laboratory Exercise Trial: 90minutes of treadmill at an intensity of 75% V02 
max. Ad libitum ingestion of water will be permined 30 and 60 minutes into 
the run. 
- Having a 30ml blood sample drawn 1, 24, 48 and 72 hours after both trials. 
- Completing a numerical rating of muscle soreness experienced during the 72 
hours after both exercise trials. 
The details of these procedures have been explained to me in full. 1 am aware that a 
certain level of discomfort may occur when the blood is taken and that the exercise trials 
will involve strenuous prolonged exercise which may be accompanied by certain medical 
risks and result in muscle soreness in the 48-72 hours post test. 1 also understand that 1 do 
not have recourse against the University in the case of an acute medical event occurring 
while I am running on the treadmill. 
I understand that participation is entirely voluntary and that I may withdraw from the 
study at anytime. 
Signed 
Date 
Principal Investigators signature 
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Average weekly running distance: _ 
Running History 
Serious\Social : _____ 
Describe normal terrain used for training (to be discussed / confirmed by athletics 
coach) 
Age s tar ted running: _ _ _ _ _ _ _ 
Level of training dur ing these years . . 
Total number of mara thons run : 
_( ...-yre) 
[Take into consideration - number of days on flat - number on hills, distance on 
bills, group training, etc) 
Other sports played in last 12 months (squash, rugby weights, etc) 
List peak event(s) for each year of training age (or last 5 years) 
List races / competitions over the last 6 months (all sports) 
List races planned for next 2 months all sports 
Any training group partner in study? If so who? 
Describe your running shoes (make model and age / distance covered) 
Describe your running foot strike (heel-toe / Forefoot / pronation) 
Do you use orthotics? 
Describe the wear pattern on your shoes? 
Personal Best times in last 12 months: 
5 km time trial 8km time trial 
15 km 21.1km 32km . 
42.2km 56 km Comrades ... 
1609m time trial time (will be tested as part of study) .., 
Pace to be used for test (will be filled in after test) 
Please sign:_ 
Principal investigator's signature: _ 
MEASUREMENTS 
Pregnancy Test( if female only).. 
Lung Function Tests 










Body fat percentage: 
ave: 
ave: 






VO 2 ~»x tes 
VO 2 




VO 2 HR RPE 
Running Speed _ 7 5 * V02 peak": 
APPENDIX D 
Trial Record 
Trial No: _ 
Name: 
Breakfast: 
Resting HR: _ 
Ambient Temperature: 



















Study Title: The effects of an anti-inflammatory homeopathic product 
on systemic markers of exercise-induced inflammatinn 
Name.. Date of Trial:. 
General post-trial pain sealed aod relaxed Post-trial pain during daily living while 
walking 


















0 = no pain at all 
5 = moderate 
10 =severe/maximal 
Quads 
